<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006555</article-id><article-id pub-id-type="pmc">PMC11859831</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics17020188</article-id><article-id pub-id-type="publisher-id">pharmaceutics-17-00188</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>AI-Driven Innovation in Skin Kinetics for Transdermal Drug Delivery: Overcoming Barriers and Enhancing Precision</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Albayati</surname><given-names>Nubul</given-names></name><xref rid="af1-pharmaceutics-17-00188" ref-type="aff">1</xref><xref rid="af2-pharmaceutics-17-00188" ref-type="aff">2</xref><xref rid="fn1-pharmaceutics-17-00188" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Talluri</surname><given-names>Sesha Rajeswari</given-names></name><xref rid="af1-pharmaceutics-17-00188" ref-type="aff">1</xref><xref rid="af2-pharmaceutics-17-00188" ref-type="aff">2</xref><xref rid="fn1-pharmaceutics-17-00188" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2728-9329</contrib-id><name><surname>Dholaria</surname><given-names>Nirali</given-names></name><xref rid="af1-pharmaceutics-17-00188" ref-type="aff">1</xref><xref rid="af2-pharmaceutics-17-00188" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Michniak-Kohn</surname><given-names>Bozena</given-names></name><xref rid="af1-pharmaceutics-17-00188" ref-type="aff">1</xref><xref rid="af2-pharmaceutics-17-00188" ref-type="aff">2</xref><xref rid="c1-pharmaceutics-17-00188" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Cirri</surname><given-names>Marzia</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-17-00188"><label>1</label>Ernest Mario School of Pharmacy, Rutgers-The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA; <email>na501@gsbs.rutgers.edu</email> (N.A.); <email>sesha.rajeswaritalluri@rutgers.edu</email> (S.R.T.); <email>nvd16@scarletmail.rutgers.edu</email> (N.D.)</aff><aff id="af2-pharmaceutics-17-00188"><label>2</label>Center for Dermal Research, Rutgers-The State University of New Jersey, 145 Bevier Road, Piscataway, NJ 08854, USA</aff><author-notes><corresp id="c1-pharmaceutics-17-00188"><label>*</label>Correspondence: <email>michniak@pharmacy.rutgers.edu</email></corresp><fn id="fn1-pharmaceutics-17-00188"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>02</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>188</elocation-id><history><date date-type="received"><day>21</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>19</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>30</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Transdermal drug delivery systems (TDDS) offer an alternative to conventional oral and injectable drug administration by bypassing the gastrointestinal tract and liver metabolism, improving bioavailability, and minimizing systemic side effects. However, widespread adoption of TDDS is limited by challenges such as the skin&#x02019;s permeability barrier, particularly the stratum corneum, and the need for optimized formulations. Factors like skin type, hydration levels, and age further complicate the development of universally effective solutions. Advances in artificial intelligence (AI) address these challenges through predictive modeling and personalized medicine approaches. Machine learning models trained on extensive molecular datasets predict skin permeability and accelerate the selection of suitable drug candidates. AI-driven algorithms optimize formulations, including penetration enhancers and advanced delivery technologies like microneedles and liposomes, while ensuring safety and efficacy. Personalized TDDS design tailors drug delivery to individual patient profiles, enhancing therapeutic precision. Innovative systems, such as sensor-integrated patches, dynamically adjust drug release based on real-time feedback, ensuring optimal outcomes. AI also streamlines the pharmaceutical process, from disease diagnosis to the prediction of drug distribution in skin layers, enabling efficient formulation development. This review highlights AI&#x02019;s transformative role in TDDS, including applications of models such as Deep Neural Networks (DNN), Artificial Neural Networks (ANN), BioSIM, COMSOL, K-Nearest Neighbors (KNN), and Set Covering Machine (SVM). These technologies revolutionize TDDS for both skin and non-skin diseases, demonstrating AI&#x02019;s potential to overcome existing barriers and improve patient care through innovative drug delivery solutions.</p></abstract><kwd-group><kwd>artificial intelligence</kwd><kwd>transdermal drug delivery</kwd><kwd>machine learning</kwd><kwd>formula optimization</kwd><kwd>BioSIM</kwd></kwd-group><funding-group><award-group><funding-source>Center for Dermal Research</funding-source></award-group><funding-statement>Funding for writing this review was provided by the Center for Dermal Research, Rutgers-The State University of New Jersey, 145 Bevier Road, Piscataway, NJ 08854.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-17-00188"><title>1. Introduction</title><p>By enabling drugs to permeate through the skin and enter systemic circulation, TDDS provides significant advantages over traditional oral and injectable routes [<xref rid="B1-pharmaceutics-17-00188" ref-type="bibr">1</xref>]. One key benefit is bypassing the first-pass metabolism in the liver, which can degrade active drug compounds, leading to reduced bioavailability [<xref rid="B2-pharmaceutics-17-00188" ref-type="bibr">2</xref>]. Additionally, TDDS supports controlled and sustained drug release, maintaining therapeutic drug levels over an extended period and improving patient compliance by reducing the frequency of administration [<xref rid="B3-pharmaceutics-17-00188" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceutics-17-00188" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceutics-17-00188" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceutics-17-00188" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceutics-17-00188" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceutics-17-00188" ref-type="bibr">8</xref>].</p><p>Despite these advantages, the efficacy of TDDS is limited by several critical factors. The most formidable challenge is the stratum corneum, the outermost layer of the skin, which acts as a robust barrier to most drugs [<xref rid="B9-pharmaceutics-17-00188" ref-type="bibr">9</xref>]. Its low permeability restricts the passage of large and hydrophilic molecules, necessitating the use of penetration enhancers, advanced delivery systems, or chemical modifications of the drug [<xref rid="B10-pharmaceutics-17-00188" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-17-00188" ref-type="bibr">11</xref>,<xref rid="B12-pharmaceutics-17-00188" ref-type="bibr">12</xref>]. Furthermore, developing effective TDDS formulations is complex, requiring a delicate balance between drug stability, release rates, and compatibility with skin physiology.</p><p>Over the past decade, research and technological advancements in transdermal drug delivery systems (TDDS) have significantly expanded. This area has seen the publication of numerous research articles and the development of innovative technologies, reflecting a strong global interest in overcoming the challenges associated with TDDS. Studies indicate a substantial increase in TDDS-related research over the past ten years, emphasizing limitations such as skin permeability and the delivery of macromolecular drugs. Techniques such as microneedles, chemical penetration enhancers (CPEs), and nanotechnology have garnered considerable research attention. Microneedles, for example, have been extensively studied for applications ranging from vaccine delivery to pain management, making them a central focus of TDDS research [<xref rid="B13-pharmaceutics-17-00188" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceutics-17-00188" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceutics-17-00188" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceutics-17-00188" ref-type="bibr">16</xref>]. Over the past decade, research in TDDS, particularly for vaccine delivery using microneedles, has significantly increased [<xref rid="B17-pharmaceutics-17-00188" ref-type="bibr">17</xref>]. Studies highlight advances in materials, fabrication techniques, and integration with biologics, reflecting TDDS&#x02019;s growing role in non-invasive, patient-friendly vaccine administration [<xref rid="B18-pharmaceutics-17-00188" ref-type="bibr">18</xref>]. Emerging technologies in transdermal drug delivery systems (TDDS) are transforming the field with innovative approaches [<xref rid="B19-pharmaceutics-17-00188" ref-type="bibr">19</xref>]. Nanocarriers such as liposomes and nanoparticles improve drug stability and targeted delivery for applications in cancer and dermatology. Techniques like electroporation and photomechanical waves temporarily disrupt the skin barrier for molecule delivery, while thermal ablation employs localized heat to enhance penetration, enabling rapid and localized drug administration [<xref rid="B20-pharmaceutics-17-00188" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceutics-17-00188" ref-type="bibr">21</xref>]. Integrating these novel approaches with AI and machine learning is also emerging as a transformative trend, facilitating formulation optimization, real-time adjustments, and enhanced patient-specific solutions. The growing body of TDDS research and innovative technology development highlights its potential to revolutionize non-invasive drug delivery.</p><p>In developing a modern TDDS for effective disease treatment, employing a predictive computational model that accurately simulates material interactions and the drug&#x02019;s skin permeability and release profile over time can save time and resources [<xref rid="B22-pharmaceutics-17-00188" ref-type="bibr">22</xref>]. Over the last decade, drug delivery has increasingly leveraged computational technology to create innovative and targeted delivery systems [<xref rid="B23-pharmaceutics-17-00188" ref-type="bibr">23</xref>].</p><p>As we progress into a new century marked by remarkable technological advancements, Machine Learning (ML) and Artificial Intelligence (AI) have emerged as powerful tools for managing and analyzing scientific data. The introduction of AI and ML methodologies has revolutionized various sectors within the medical field, mainly benefiting the pharmaceutical industry. The term &#x0201c;Artificial Intelligence&#x0201d; was first coined by John McCarthy in 1956 [<xref rid="B24-pharmaceutics-17-00188" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceutics-17-00188" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceutics-17-00188" ref-type="bibr">26</xref>]. AI is the capacity of the computer to mimic human cognitive skills and thought processes and to translate into informative solutions from complex sets of data [<xref rid="B27-pharmaceutics-17-00188" ref-type="bibr">27</xref>].</p><p>AI is a computer system replicating human cognitive functions and thought processes, transforming complex data sets into meaningful insights [<xref rid="B27-pharmaceutics-17-00188" ref-type="bibr">27</xref>]. Artificial intelligence (AI) and machine learning (ML) advancements have begun changing the landscape of TDDS research and development. These technologies streamline the design and optimization processes by analyzing large datasets, predicting drug-skin interactions, and identifying ideal formulation components. AI algorithms can model the permeation behavior of drugs, assess the impact of excipients, and optimize the physical and chemical properties of delivery systems. With the rising interest in AI&#x02019;s capabilities to analyze and interpret a wide range of information&#x02014;from genetic data to clinical applications of therapeutics&#x02014;AI can significantly accelerate the traditionally lengthy drug discovery-to-marketing process <xref rid="pharmaceutics-17-00188-f001" ref-type="fig">Figure 1</xref> [<xref rid="B28-pharmaceutics-17-00188" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-17-00188" ref-type="bibr">29</xref>].</p><p>AI can significantly transform the process of determining drug suitability for skin delivery formulation, impacting everything from drug manufacturing to marketing. As a powerful tool, AI presents a remarkable opportunity for advancements in drug discovery, redesigning, formulation, and testing of pharmaceutical dosage forms [<xref rid="B30-pharmaceutics-17-00188" ref-type="bibr">30</xref>].</p><p>With deep neural network (DNN) models, AI can detect skin diseases and predict the condition of the skin based on digital images. This AI-assisted information plays a crucial role in making informed decisions at the early stages of drug discovery and formulation and in modulating a drug&#x02019;s therapeutic exposure within the body. AI is particularly valuable in formulation design and optimization, focusing on smart drug-carrier choices for dermal delivery, which has become a trend in addressing various dermal diseases and enhancing the skin-care cosmetic industry. The accurate prediction of drug deposition in the skin from various transdermal drug delivery systems (TDDS) is essential information for formulation development. AI and machine learning (ML) algorithms now provide the means to unlock this vital information, offering actionable insights for effective disease detection and formulation design [<xref rid="B22-pharmaceutics-17-00188" ref-type="bibr">22</xref>].</p><p>Dynamic AI and ML-derived models are discussed in this review, for example, the pharmacokinetic prediction model BIOiSIM for drug exposure &#x00026; distribution prediction [<xref rid="B31-pharmaceutics-17-00188" ref-type="bibr">31</xref>], a computation model COMSOL providing estimates about the temperature effect on the skin-absorption of the drug [<xref rid="B32-pharmaceutics-17-00188" ref-type="bibr">32</xref>], utilization of a computation model referenced as ANN (Artificial Neural Network) for predicting the efficacy of two medications for COVID-19 [<xref rid="B33-pharmaceutics-17-00188" ref-type="bibr">33</xref>], have fueled the importance of such AI and ML based approaches in a pharmaceutical field. Other ML-based models such as K-Nearest Neighbors (KNN), Set Covering Machine (SVM), and Deep Neural Network (DNN) are discussed for their ability to predict the active protease inhibitor site for the treatment of HIV-1 [<xref rid="B34-pharmaceutics-17-00188" ref-type="bibr">34</xref>].</p><p>Furthermore, AI-driven systems enable the development of smart transdermal devices that monitor real-time physiological parameters and adjust drug release dynamically to ensure consistent therapeutic outcomes. This convergence of AI and TDDS holds the potential to overcome traditional barriers and pave the way for innovative, personalized, and efficient drug delivery solutions.</p></sec><sec id="sec2-pharmaceutics-17-00188"><title>2. Emerging TDDS for the Treatment of Viral Infections and Other Vital Organ Disorders</title><sec id="sec2dot1-pharmaceutics-17-00188"><title>2.1. TDDS for the Treatment of Viral Infections</title><p>TDDS are particularly effective for treating skin-based viral infections, as it allows for targeted application directly to affected areas. This method also minimizes systemic absorption and reduces related side effects [<xref rid="B35-pharmaceutics-17-00188" ref-type="bibr">35</xref>]. By utilizing advanced techniques to deliver innovative nanocarriers to the target site, the goal is to significantly lower viral loads more effectively than standard drug dosage forms [<xref rid="B36-pharmaceutics-17-00188" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceutics-17-00188" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceutics-17-00188" ref-type="bibr">38</xref>]. Transdermal administration is considered the most suitable for controlling cutaneous viral infections such as herpes, chickenpox [<xref rid="B37-pharmaceutics-17-00188" ref-type="bibr">37</xref>,<xref rid="B39-pharmaceutics-17-00188" ref-type="bibr">39</xref>], warts [<xref rid="B38-pharmaceutics-17-00188" ref-type="bibr">38</xref>,<xref rid="B40-pharmaceutics-17-00188" ref-type="bibr">40</xref>], and influenza [<xref rid="B41-pharmaceutics-17-00188" ref-type="bibr">41</xref>]. Recent studies suggest that transdermal delivery could be an alternative route for administering COVID-19 vaccines [<xref rid="B37-pharmaceutics-17-00188" ref-type="bibr">37</xref>,<xref rid="B39-pharmaceutics-17-00188" ref-type="bibr">39</xref>,<xref rid="B41-pharmaceutics-17-00188" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceutics-17-00188" ref-type="bibr">42</xref>]. A penciclovir-loaded hydrogel nanoemulsion (HN) was developed for transdermal herpes simplex treatment, demonstrating double the permeation efficiency of a marketed cream in vitro using porcine skin. This promising formulation demonstrated enhanced drug delivery through comparative percutaneous absorption studies [<xref rid="B43-pharmaceutics-17-00188" ref-type="bibr">43</xref>]. A comparative study examined binary ethosomes (ETHOs) and elastic liposomes (ELPs) for transdermal delivery of sodium salt Acyclovir (ACV-Na). The evaluation included in-vitro release, ex-vivo permeation, and skin deposition, showing that optimized ETHOs significantly enhanced permeation flux and drug deposition compared to ELPs. Safety assessments through hemolysis and skin irritation analyses indicated that ETHOs are a promising alternative to traditional vesicular systems for improved skin permeation and stability in transdermal applications. A study formulated an oil-in-water (o/w) microemulsion using these enhancers for transdermal delivery of acyclovir, which was tested for efficacy in a murine model of zosteriform cutaneous HSV-1 infection [<xref rid="B41-pharmaceutics-17-00188" ref-type="bibr">41</xref>,<xref rid="B44-pharmaceutics-17-00188" ref-type="bibr">44</xref>]. Influenza vaccine-loaded egg microneedles (FLU-EMN) were designed and characterized, highlighting their potential for effective and minimally invasive delivery of therapeutic drugs without the need for cold storage [<xref rid="B45-pharmaceutics-17-00188" ref-type="bibr">45</xref>]. This microneedle system could become an effective method for nationwide vaccination, making the process more cost-effective, safe, and feasible. Microneedles rapidly activate therapeutic properties. A minimally invasive microneedle array patch (MAP) was developed to deliver Zanamivir, achieving higher lung tissue concentrations and demonstrating potential as an innovative treatment for seasonal influenza [<xref rid="B46-pharmaceutics-17-00188" ref-type="bibr">46</xref>]. Microneedle drug delivery has shown promise in treating plantar warts caused by HPV. Ghonemy et al. reported that combining microneedling with 5-fluorouracil (5-FU) achieved an 86.7% complete response rate, outperforming intralesional 5-FU (76.7%) and microneedling alone (70%), with improved patient satisfaction due to reduced discomfort [<xref rid="B40-pharmaceutics-17-00188" ref-type="bibr">40</xref>]. Numerous SARS-CoV-2 vaccines have been developed since the COVID-19 outbreak, with 242 candidates in clinical development and 11 approved for emergency use by WHO. While most vaccines require subcutaneous or intramuscular administration, transdermal delivery offers a promising alternative, particularly for self-administration in resource-limited areas. A fluorocarbon-modified chitosan-based transdermal system was shown to effectively deliver the SARS-CoV-2 vaccine, generating immune responses comparable to subcutaneous injections by activating immune cells and targeting lymph nodes [<xref rid="B47-pharmaceutics-17-00188" ref-type="bibr">47</xref>]. A microneedle array (MNA) was developed to deliver the SARS-CoV-2 S1 subunit vaccine, targeting the spike protein to prevent infection. MNAs expedite vaccine production and reduce costs by requiring fewer doses. These MNA-based vaccines generate strong antibody responses, and stability studies suggest that integrating vaccine components into the MNA polymer matrix preserves their structure and binding functions. These MNAs are designed for self-administration, eliminating the need for specialized equipment [<xref rid="B42-pharmaceutics-17-00188" ref-type="bibr">42</xref>]. A comprehensive list of viral infections treated using TDDS is presented in <xref rid="pharmaceutics-17-00188-t001" ref-type="table">Table 1</xref> below.</p></sec><sec id="sec2dot2-pharmaceutics-17-00188"><title>2.2. TDDS for the Treatment of Central Nervous System (CNS) Disorders</title><p>Significant Progress has been made in developing transdermal formulations for treating central nervous system disorders. Transdermal drug delivery systems (TDDS) that include nicotinic agonists, particularly nicotine, are commonly used to assist in smoking cessation and to help manage withdrawal symptoms [<xref rid="B49-pharmaceutics-17-00188" ref-type="bibr">49</xref>,<xref rid="B50-pharmaceutics-17-00188" ref-type="bibr">50</xref>]. These agents have also shown potential in alleviating cognitive impairments associated with neurodegenerative diseases and psychiatric conditions such as schizophrenia and attention disorders [<xref rid="B51-pharmaceutics-17-00188" ref-type="bibr">51</xref>,<xref rid="B52-pharmaceutics-17-00188" ref-type="bibr">52</xref>,<xref rid="B53-pharmaceutics-17-00188" ref-type="bibr">53</xref>]. Transdermal nicotine has been observed to improve symptoms of ADHD, although the underlying mechanisms remain unclear. This improvement may be linked to nicotine&#x02019;s ability to increase dopamine release, which is also enhanced by conventional ADHD treatments like methylphenidate and amphetamine [<xref rid="B53-pharmaceutics-17-00188" ref-type="bibr">53</xref>]. Research conducted by eminent scientists has introduced a new methylphenidate patch designed for long-term Attention-Deficit/Hyperactivity Disorder (ADHD) management. This patch functions as both an adhesive and a drug reservoir, allowing dosage adjustments based on patch size and wear duration to personalize treatment [<xref rid="B51-pharmaceutics-17-00188" ref-type="bibr">51</xref>].</p><p>Furthermore, a study led by Sittl et al. demonstrated the effectiveness of a transdermal buprenorphine system for managing severe chronic pain from conditions like cancer, reducing the need for oral medications. This system has been associated with improved sleep duration and generally mild to moderate side effects commonly seen with opioid therapy [<xref rid="B49-pharmaceutics-17-00188" ref-type="bibr">49</xref>]. Another notable development is a transdermal system integrating the antidepressant selegiline, which effectively inhibits central monoamine oxidase A (MAO-A) and B (MAO-B) enzymes. While its antidepressant effects are modest, it avoids metabolism by the liver and intestines, enhancing its therapeutic advantage [<xref rid="B54-pharmaceutics-17-00188" ref-type="bibr">54</xref>]. Several commercially available TDDSs target the central nervous system (CNS), such as Neupro, a rotigotine system for early-stage Parkinson&#x02019;s disease, and nicotine patches (Nicotinell, Nicodern, Prostep) for smoking cessation. Other products include Matrifen and Duragesic systems containing fentanyl for pain management and Transderm-Scop for motion sickness. Specialized transdermal buprenorphine devices are also available for treating sickle cell disease-related pain [<xref rid="B55-pharmaceutics-17-00188" ref-type="bibr">55</xref>]. Early clinical trials have shown limited success for acetylcholinesterase inhibitors (AChEIs) like TTS-physostigmine and TTS-tacrine, lacking sufficient evidence of efficacy beyond a placebo [<xref rid="B56-pharmaceutics-17-00188" ref-type="bibr">56</xref>,<xref rid="B57-pharmaceutics-17-00188" ref-type="bibr">57</xref>]. However, transdermal rivastigmine has been effective in reducing cognitive and functional impairments in Alzheimer&#x02019;s disease patients [<xref rid="B58-pharmaceutics-17-00188" ref-type="bibr">58</xref>]. A comprehensive list of drugs administered through TDDS is detailed in <xref rid="pharmaceutics-17-00188-t002" ref-type="table">Table 2</xref>.</p></sec><sec id="sec2dot3-pharmaceutics-17-00188"><title>2.3. TDDS for the Treatment of Cardiovascular (CV) Diseases</title><p>In a heart failure (HF) scenario, the drug&#x02019;s pharmacokinetics (PK), pharmacodynamics (PD), and tolerability are frequently impacted by changes in the body&#x02019;s physiological parameters from hypoperfusion systemic conditions due to reduced cardiac ejection fraction [<xref rid="B77-pharmaceutics-17-00188" ref-type="bibr">77</xref>]. In addition, drug metabolism and metabolite clearance are reduced in renal failure [<xref rid="B78-pharmaceutics-17-00188" ref-type="bibr">78</xref>]&#x02014;co-morbid conditions like hypoalbuminemia and hepatic congestion impair drug absorption [<xref rid="B79-pharmaceutics-17-00188" ref-type="bibr">79</xref>].</p><p>Therefore, transdermal patch delivery systems may offer an effective solution for drug administration. Propranolol, a nonselective beta-adrenergic blocker, undergoes significant hepatic first-pass metabolism when taken orally, leading to a bioavailability of about 23% [<xref rid="B80-pharmaceutics-17-00188" ref-type="bibr">80</xref>]. An animal study with rabbits demonstrated that oral propranolol achieved a Cmax of 56.4 ng/mL within 13.2 min, but due to liver metabolism, its bioavailability was only 12.3% [<xref rid="B81-pharmaceutics-17-00188" ref-type="bibr">81</xref>]. Conversely, the transdermal propranolol patch reached a steady-state plasma concentration (Css) of 9.3 ng/mL after an initial lag time of 8 h, with a bioavailability that was 74.8% higher than that of oral propranolol [<xref rid="B82-pharmaceutics-17-00188" ref-type="bibr">82</xref>].</p><p>Nitroglycerin is another significant drug in cardiovascular therapy. Lauder &#x00026; Blanton used nitroglycerin to relieve angina pectoris and first observed drug resistance after repeated doses in 1867 [<xref rid="B83-pharmaceutics-17-00188" ref-type="bibr">83</xref>]. Ferid Murad discovered that nitric oxide (NO) from nitroglycerin acts on vascular smooth muscle by activating cyclic guanosine monophosphate (cGMP), leading to vasodilation [<xref rid="B84-pharmaceutics-17-00188" ref-type="bibr">84</xref>]. A two-way crossover study was conducted on twenty-five healthy males using Nitro-Dur and another type of nitroglycerin transdermal patch, Nitro-Dur II, which showed average Cmax values of 0.383 ng/mL and 0.432 ng/mL, respectively [<xref rid="B85-pharmaceutics-17-00188" ref-type="bibr">85</xref>].</p><p>Bisono<sup>&#x000ae;</sup> Tape is a transdermal patch containing bisoprolol as an active ingredient [<xref rid="B86-pharmaceutics-17-00188" ref-type="bibr">86</xref>], used to manage conditions such as aortic dissection [<xref rid="B87-pharmaceutics-17-00188" ref-type="bibr">87</xref>], premature ventricular contraction [<xref rid="B88-pharmaceutics-17-00188" ref-type="bibr">88</xref>], orthostatic hypotension due to heart failure [<xref rid="B89-pharmaceutics-17-00188" ref-type="bibr">89</xref>], and atrial fibrillation [<xref rid="B90-pharmaceutics-17-00188" ref-type="bibr">90</xref>]. A comparative study involving edematous and non-edematous patients using the Bisono<sup>&#x000ae;</sup> Tape 4 mg patch showed that the Cmax was 13.3 ng/mL in the edema group and 17 ng/mL in the non-edema group [<xref rid="B91-pharmaceutics-17-00188" ref-type="bibr">91</xref>]. This study aimed to investigate the effect of systemic edema on the absorption of beta-blockers from skin patches in critically ill patients. However, it was found that systemic edema of the lower extremities did not affect the blood levels or the heart rate-lowering effects of bisoprolol after applying the bisoprolol skin patch.</p><p>Another antihypertensive drug that utilizes transdermal patch delivery is clonidine. Clonidine is an &#x003b1;2-adrenergic agonist initially used to treat hypertension [<xref rid="B91-pharmaceutics-17-00188" ref-type="bibr">91</xref>]. It has also been used for conditions such as attention-deficit hyperactivity disorder (ADHD) [<xref rid="B92-pharmaceutics-17-00188" ref-type="bibr">92</xref>] and drug withdrawal syndrome [<xref rid="B93-pharmaceutics-17-00188" ref-type="bibr">93</xref>]. The transdermal clonidine patch was introduced in 1983 and approved by the FDA in 1984 [<xref rid="B94-pharmaceutics-17-00188" ref-type="bibr">94</xref>,<xref rid="B95-pharmaceutics-17-00188" ref-type="bibr">95</xref>]. Since then, a comparative study of oral and transdermal clonidine has been conducted [<xref rid="B96-pharmaceutics-17-00188" ref-type="bibr">96</xref>]. The results showed no difference in Cmax between oral clonidine (0.39 ng/mL) and transdermal clonidine (0.3 ng/mL), but the half-life of transdermal clonidine was longer than that of oral clonidine (31.9 h vs. 10.8 h). Additionally, there was no difference in the antihypertensive effect [<xref rid="B96-pharmaceutics-17-00188" ref-type="bibr">96</xref>].</p><p>Losartan, an angiotensin II receptor blocker (ARB), is also being developed for transdermal drug delivery. A previous study on rat skin with proniosome transdermal drug delivery showed that transdermal losartan achieved a Cmax of 141 ng/mL compared to 152 ng/mL when taken orally. However, the bioavailability of transdermal losartan was 1.93 times that of oral losartan [<xref rid="B97-pharmaceutics-17-00188" ref-type="bibr">97</xref>]. Various cardiovascular drugs formulated as transdermal delivery systems are listed in <xref rid="pharmaceutics-17-00188-t003" ref-type="table">Table 3</xref>.</p></sec><sec id="sec2dot4-pharmaceutics-17-00188"><title>2.4. TDDS for the Treatment of Other Complications Such as Hormonal Imbalance and Autoimmune Disorders</title><p>Transdermal drug delivery systems (TDDS) have shown promise in managing conditions like hormonal imbalances and autoimmune disorders. For hormonal imbalances, TDDS offers an effective method for administering hormones such as estrogen, testosterone, and progesterone, often in patches or gels [<xref rid="B109-pharmaceutics-17-00188" ref-type="bibr">109</xref>]. These systems allow for controlled, continuous release of the hormone, bypassing first-pass metabolism in the liver and providing a steady, more predictable therapeutic effect. For example, transdermal patches for hormone replacement therapy (HRT) are widely used for menopausal symptoms and androgen deficiency in men [<xref rid="B110-pharmaceutics-17-00188" ref-type="bibr">110</xref>]. In autoimmune disorders like rheumatoid arthritis and psoriasis, TDDS has been explored to deliver anti-inflammatory and immunosuppressive drugs directly to the affected areas, minimizing systemic side effects [<xref rid="B111-pharmaceutics-17-00188" ref-type="bibr">111</xref>]. Recent innovations, such as microneedles and smart patches, enhance the precision of drug delivery, improve patient compliance, and allow personalized treatments [<xref rid="B112-pharmaceutics-17-00188" ref-type="bibr">112</xref>]. The potential for integrating AI-driven formulation optimization further enhances the effectiveness of TDDS in managing these chronic and complex conditions. <xref rid="pharmaceutics-17-00188-t004" ref-type="table">Table 4</xref> is focused on TDDS for the treatment of hormonal imbalance and pain management with examples of drugs and transdermal drug delivery systems (TDDS), along with references:</p></sec></sec><sec id="sec3-pharmaceutics-17-00188"><title>3. Application of AI in Various Stages of TDDS</title><sec id="sec3dot1-pharmaceutics-17-00188"><title>3.1. Screening of Drug Molecules and Optimizing Formula</title><p>AI can identify molecules with ideal physicochemical properties (e.g., solubility and lipophilicity) for transdermal delivery, saving time and resources in drug development. Machine learning (ML) algorithms predict the optimal formulation of drugs and excipients, enhancing drug permeation through the skin [<xref rid="B30-pharmaceutics-17-00188" ref-type="bibr">30</xref>]. Techniques like quantitative structure-activity relationships (QSAR) modeling and advanced deep learning methods allow researchers to predict molecular interactions and properties [<xref rid="B125-pharmaceutics-17-00188" ref-type="bibr">125</xref>], streamlining the identification of suitable candidates for TDDS. Machine learning (ML) algorithms can predict the optimal formulation of drugs and excipients, enhancing drug permeation through the skin.</p></sec><sec id="sec3dot2-pharmaceutics-17-00188"><title>3.2. Skin Permeability Prediction</title><p>AI models analyze large datasets of skin permeability for various compounds, predicting their suitability for transdermal delivery. AI helps adjust formulations based on the skin type, condition (e.g., hydration), and target drug. The study conducted by Abdallah et al. focuses on using AI algorithms to predict skin permeability (LogKp) for FDA-approved drugs based on molecular structures. It applies regression models and clustering techniques to analyze permeability patterns, aiding in selecting drug candidates for transdermal formulations [<xref rid="B126-pharmaceutics-17-00188" ref-type="bibr">126</xref>]. A study conducted by Defraeye et al. focuses on using AI algorithms to predict skin permeability (LogKp) for FDA-approved drugs based on molecular structures [<xref rid="B127-pharmaceutics-17-00188" ref-type="bibr">127</xref>]. A recent review of developments in modeling the skin&#x02019;s microstructure using finite element modeling emphasized integrating advanced techniques to simulate the absorption of drugs and cosmetics, improving the representation of the skin&#x02019;s physical properties [<xref rid="B128-pharmaceutics-17-00188" ref-type="bibr">128</xref>]. A comprehensive dataset on FDA-approved drugs was analyzed using advanced machine learning techniques such as ensemble methods (e.g., Random Forest and XGBoost) and artificial neural networks (ANNs). These models predicted skin permeability (LogKp values) and demonstrated enhanced accuracy for drug diffusion properties in transdermal systems [<xref rid="B126-pharmaceutics-17-00188" ref-type="bibr">126</xref>].</p></sec><sec id="sec3dot3-pharmaceutics-17-00188"><title>3.3. Design and Optimization of Delivery Systems</title><p>AI significantly enhances the design and optimization of transdermal patches by analyzing multiple parameters such as geometry, adhesive properties, and material composition [<xref rid="B129-pharmaceutics-17-00188" ref-type="bibr">129</xref>]. AI-driven models predict the impact of patch design variables on drug release profiles, ensuring consistent delivery rates. For instance, machine learning algorithms can identify the optimal combination of adhesive layers and matrix materials to balance adhesion with drug diffusion. Moreover, AI enables the customization of patches for specific patient needs, such as varying skin types and drug absorption rates. Advanced simulation techniques also allow researchers to predict patch performance under different environmental and physiological conditions [<xref rid="B130-pharmaceutics-17-00188" ref-type="bibr">130</xref>]. The design of microneedles benefits from machine learning, which refines parameters such as length, tip sharpness, and material selection to maximize efficiency while minimizing discomfort. AI tools assess the interaction between microneedles and skin to optimize penetration depth and drug diffusion without causing significant pain or damage. Moreover, AI facilitates the development of biodegradable microneedles, ensuring safe and effective drug delivery. Simulation-based approaches allow rapid prototyping of microneedle arrays, reducing development time and resource usage. These innovations make microneedles suitable for applications ranging from vaccine delivery to hormone therapies [<xref rid="B131-pharmaceutics-17-00188" ref-type="bibr">131</xref>,<xref rid="B132-pharmaceutics-17-00188" ref-type="bibr">132</xref>,<xref rid="B133-pharmaceutics-17-00188" ref-type="bibr">133</xref>,<xref rid="B134-pharmaceutics-17-00188" ref-type="bibr">134</xref>].</p></sec><sec id="sec3dot4-pharmaceutics-17-00188"><title>3.4. Personalized Medicine</title><p>Smart patches integrated with AI-enabled sensors can monitor drug levels in the body and adjust delivery dynamically. Smart patches with AI-enabled sensors represent a revolutionary leap in TDDS [<xref rid="B135-pharmaceutics-17-00188" ref-type="bibr">135</xref>]. These systems dynamically monitor drug levels in real-time and adapt delivery rates as needed, ensuring that therapeutic levels are maintained consistently. This feedback mechanism minimizes risks of over- or under-dosing while improving patient outcomes. The integration of such technologies not only enhances treatment efficacy but also improves patient adherence by reducing complexity. AI systems analyze patient data (e.g., skin type, age, and medical history) to tailor drug doses and delivery schedules. AI algorithms leverage patient-specific data, including skin characteristics, genetic profiles, and medical history, to design individualized drug regimens. These systems could be used to analyze variations in skin permeability and health conditions, enabling precise optimization of drug dosage and delivery schedules tailored to each patient&#x02019;s unique needs [<xref rid="B136-pharmaceutics-17-00188" ref-type="bibr">136</xref>].</p></sec><sec id="sec3dot5-pharmaceutics-17-00188"><title>3.5. Simulation and Virtual Testing</title><p>Skin Models: There are multiple test models for predicting dermal absorption, many of which depend on ex vivo animal or human models. However, growing restrictions on animal and human skin use, combined with significant differences in dermal composition&#x02014;such as hair follicle density and skin thickness between various species&#x02014;complicate accurate predictions of pharmacokinetics (PK) in humans. In recent years, the incorporation of AI algorithms has transformed the pharmaceutical industry, reinventing drug development through large-scale systems and a big data-driven approach. AI studies how computers and machine learning systems imitate human intelligence using computational techniques to solve human problems. Hence, using AI and machine learning, one can explore predicting dermal exposure of therapeutics and evaluating the impact of different formulations on transdermal disposition.</p><p>AI-driven simulations replicate drug interactions with skin layers, including the stratum corneum, epidermis, and dermis. These models provide detailed insights into the mechanisms of drug permeation, reducing dependency on traditional in vitro or in vivo experiments. For instance, computational techniques such as compartmental and diffusion models use differential equations to describe the movement of drugs through skin layers [<xref rid="B137-pharmaceutics-17-00188" ref-type="bibr">137</xref>]. These simulations effectively assess the penetration of various drug types and evaluate their potential for transdermal delivery, often replacing or complementing &#x0201c;skin-on-a-chip&#x0201d; technologies [<xref rid="B138-pharmaceutics-17-00188" ref-type="bibr">138</xref>]. AI-powered predictive models forecast outcomes of drug delivery in diverse scenarios, such as varying patient conditions and drug formulations. Such models utilize large datasets to train machine learning algorithms that evaluate parameters like drug permeability, stability, and absorption. By predicting the performance of formulations before physical trials, these methods streamline the development process and minimize costs. Recent innovations, such as microfluidic &#x0201c;skin-on-a-chip&#x0201d; systems, mimic the physiological properties of human skin more accurately than traditional methods [<xref rid="B139-pharmaceutics-17-00188" ref-type="bibr">139</xref>]. These devices integrate sensors to monitor real-time changes and effects of drug delivery, providing high-resolution data for validating AI-based predictions. These advancements underscore the potential of combining AI with advanced simulation techniques to revolutionize TDDS, making drug development faster, more cost-effective, and ethically sustainable. In a study by Maharao et al. [<xref rid="B140-pharmaceutics-17-00188" ref-type="bibr">140</xref>], a revolutionary transdermal model was developed and validated using a BIOiSIM platform. This platform operates on dynamic drug pharmacokinetic predictions driven by biological inputs. Integrating machine learning and physiological modeling, BIOiSIM offers a scalable computational solution to make accurate and rapid predictions. It employs a 16-compartment model to simulate and predict the exposure of three distinct drug-like compounds&#x02014;morphine, buprenorphine, and nicotine&#x02014;both chemically and biologically. The model effectively predicts their distribution with an average fold error of less than two, showcasing its accuracy in forecasting compound distributions through the skin [<xref rid="B140-pharmaceutics-17-00188" ref-type="bibr">140</xref>].</p></sec><sec id="sec3dot6-pharmaceutics-17-00188"><title>3.6. Efficiency in Clinical Trials</title><p>AI has significantly enhanced the efficiency of clinical trials in various aspects, especially for transdermal drug delivery systems (TDDS). Regarding patient recruitment, AI excels by analyzing vast datasets, including electronic health records (EHRs), social media platforms, and genetic data, to identify suitable candidates faster and more accurately. This targeted approach improves trial validity by ensuring that participants are more likely to benefit from the tested treatment [<xref rid="B141-pharmaceutics-17-00188" ref-type="bibr">141</xref>]. Moreover, AI can enhance retention by detecting at-risk patients early and providing timely interventions, such as automated reminders, thus improving adherence to the trial protocol. AI also streamlines data collection and analysis, minimizing errors and significantly reducing the time required for these processes. By automating data integration from various sources like medical records and wearables, AI ensures consistency and accuracy, which is crucial for maintaining high-quality data. Additionally, AI aids in predictive modeling, helping researchers anticipate trial outcomes and adapt designs based on interim results, thus preventing delays or protocol failures. These AI-driven advancements have the potential to shorten trial durations, reduce costs, and improve overall trial success rates, especially by optimizing recruitment, data analysis, and outcome prediction [<xref rid="B142-pharmaceutics-17-00188" ref-type="bibr">142</xref>].</p></sec><sec id="sec3dot7-pharmaceutics-17-00188"><title>3.7. Approaches to Resolve Problems</title><p>AI significantly enhances drug penetration and reduces variability in transdermal drug delivery systems (TDDS). Penetration enhancers are critical for improving the skin&#x02019;s permeability to drugs, especially those with low natural penetration properties. AI aids in identifying new enhancers by analyzing molecular interactions and predicting their effectiveness. For instance, AI-based models can predict how certain compounds, like dimethyl sulfoxide (DMSO) or azone, influence the structure of the stratum corneum and promote better drug transport across the skin. Additionally, AI helps address variability in skin response, which varies across populations due to age, skin type, and environmental conditions. Machine learning algorithms can analyze large datasets of skin responses to different transdermal systems, identifying patterns that lead to more consistent and effective drug delivery across diverse patient groups. These technologies enable the development of more personalized and efficient TDDS tailored to specific patient needs and conditions [<xref rid="B126-pharmaceutics-17-00188" ref-type="bibr">126</xref>].</p><p>Over the decades, various mechanisms have been proposed to explain how temperature influences skin permeability and flux in ex vivo human skin. However, there is still limited understanding of why temperature influences drug absorption. However, understanding the specific reasons behind temperature affecting drug absorption remains limited. Therefore, connecting the transient and steady-state temperature changes to drug transport across the stratum corneum (SC) and its effects on dermal clearance and systemic pharmacokinetics (PK) is crucial. La Count et al. introduced a model to address simultaneous heat and mass transport using COMSOL software version 5.3, focusing on the effects of transient and steady-state temperatures on nicotine absorption in the skin. Their model, grounded in extensive literature analysis, was validated against human in vivo and in vitro data for nicotine. Notably, the results indicated that a 10 &#x000b0;C increase in skin surface temperature correlates with a twofold increase in nicotine absorption, suggesting an activation energy of 50&#x02013;65 kJ/mol for diffusion in the stratum corneum, which acts as the main barrier to nicotine absorption [<xref rid="B32-pharmaceutics-17-00188" ref-type="bibr">32</xref>]. This model holds promise for applications in designing transdermal delivery systems, particularly for estimating how heat affects systemic drug levels in experimental IVPT data and systemic PK data. The potential of AI in resolving the drug delivery issues in transdermal drug delivery is indicated in tabular column 5 (<xref rid="pharmaceutics-17-00188-t005" ref-type="table">Table 5</xref>).</p></sec></sec><sec id="sec4-pharmaceutics-17-00188"><title>4. Future Potential of AI in Overcoming Obstacles in TDDS</title><p>Though the engagement of ML and leveraging AI can accelerate the development of safe and effective disease treatments, a few drawbacks are addressed in tabular column 6 (<xref rid="pharmaceutics-17-00188-t006" ref-type="table">Table 6</xref>).</p><p>With advancements in AI, these drawbacks could be resolved. TDDS can become more efficient, precise, and adaptable, paving the way for breakthroughs in drug delivery technology. For instance, integrating AI with nanotechnology in TDDS may lead to novel delivery platforms that can target diseases with unparalleled specificity.</p></sec></body><back><ack><title>Acknowledgments</title><p>This review used ChatGPT Version 4 for language refinement and paraphrasing and Grammarly for grammatical accuracy.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>N.A. and S.R.T.: Contributed equally to the article in conceptualizing, writing, and data analysis. N.D.: conducted the literature search, reviewed the manuscript, and provided critical feedback. B.M.-K.: Supervised the work and contributed to the final editing of the manuscript. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-17-00188"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alkilani</surname><given-names>A.Z.</given-names></name>
<name><surname>Nasereddin</surname><given-names>J.</given-names></name>
<name><surname>Hamed</surname><given-names>R.</given-names></name>
<name><surname>Nimrawi</surname><given-names>S.</given-names></name>
<name><surname>Hussein</surname><given-names>G.</given-names></name>
<name><surname>Abo-Zour</surname><given-names>H.</given-names></name>
<name><surname>Donnelly</surname><given-names>R.F.</given-names></name>
</person-group><article-title>Beneath the skin: A review of current trends and future prospects of transdermal drug delivery systems</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>1152</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14061152</pub-id><pub-id pub-id-type="pmid">35745725</pub-id>
</element-citation></ref><ref id="B2-pharmaceutics-17-00188"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zaid Alkilani</surname><given-names>A.</given-names></name>
<name><surname>McCrudden</surname><given-names>M.T.</given-names></name>
<name><surname>Donnelly</surname><given-names>R.F.</given-names></name>
</person-group><article-title>Transdermal drug delivery: Innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum</article-title><source>Pharmaceutics</source><year>2015</year><volume>7</volume><fpage>438</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.3390/pharmaceutics7040438</pub-id><pub-id pub-id-type="pmid">26506371</pub-id>
</element-citation></ref><ref id="B3-pharmaceutics-17-00188"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jeong</surname><given-names>W.Y.</given-names></name>
<name><surname>Kwon</surname><given-names>M.</given-names></name>
<name><surname>Choi</surname><given-names>H.E.</given-names></name>
<name><surname>Kim</surname><given-names>K.S.</given-names></name>
</person-group><article-title>Recent advances in transdermal drug delivery systems: A review</article-title><source>Biomater. Res.</source><year>2021</year><volume>25</volume><elocation-id>24</elocation-id><pub-id pub-id-type="doi">10.1186/s40824-021-00226-6</pub-id><pub-id pub-id-type="pmid">34321111</pub-id>
</element-citation></ref><ref id="B4-pharmaceutics-17-00188"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>N.</given-names></name>
<name><surname>Dubey</surname><given-names>A.</given-names></name>
<name><surname>Mishra</surname><given-names>A.</given-names></name>
<name><surname>Tiwari</surname><given-names>P.</given-names></name>
</person-group><article-title>Ethosomes: A Novel Approach in Transdermal Drug Delivery System</article-title><source>Int. J. Pharm. Life Sci.</source><year>2020</year><volume>11</volume><fpage>6598</fpage><lpage>6608</lpage></element-citation></ref><ref id="B5-pharmaceutics-17-00188"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prausnitz</surname><given-names>M.R.</given-names></name>
</person-group><article-title>A practical assessment of transdermal drug delivery by skin electroporation</article-title><source>Adv. Drug Deliv. Rev.</source><year>1999</year><volume>35</volume><fpage>61</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/S0169-409X(98)00063-5</pub-id><pub-id pub-id-type="pmid">10837689</pub-id>
</element-citation></ref><ref id="B6-pharmaceutics-17-00188"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Phatale</surname><given-names>V.</given-names></name>
<name><surname>Vaiphei</surname><given-names>K.K.</given-names></name>
<name><surname>Jha</surname><given-names>S.</given-names></name>
<name><surname>Patil</surname><given-names>D.</given-names></name>
<name><surname>Agrawal</surname><given-names>M.</given-names></name>
<name><surname>Alexander</surname><given-names>A.</given-names></name>
</person-group><article-title>Overcoming skin barriers through advanced transdermal drug delivery approaches</article-title><source>J. Control. Release</source><year>2022</year><volume>351</volume><fpage>361</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.09.025</pub-id><pub-id pub-id-type="pmid">36169040</pub-id>
</element-citation></ref><ref id="B7-pharmaceutics-17-00188"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ramadon</surname><given-names>D.</given-names></name>
<name><surname>McCrudden</surname><given-names>M.T.</given-names></name>
<name><surname>Courtenay</surname><given-names>A.J.</given-names></name>
<name><surname>Donnelly</surname><given-names>R.F.</given-names></name>
</person-group><article-title>Enhancement strategies for transdermal drug delivery systems: Current trends and applications</article-title><source>Drug Deliv. Transl. Res.</source><year>2021</year><volume>12</volume><fpage>758</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1007/s13346-021-00909-6</pub-id><pub-id pub-id-type="pmid">33474709</pub-id>
</element-citation></ref><ref id="B8-pharmaceutics-17-00188"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sala</surname><given-names>M.</given-names></name>
<name><surname>Diab</surname><given-names>R.</given-names></name>
<name><surname>Elaissari</surname><given-names>A.</given-names></name>
<name><surname>Fessi</surname><given-names>H.</given-names></name>
</person-group><article-title>Lipid nanocarriers as skin drug delivery systems: Properties, mechanisms of skin interactions and medical applications</article-title><source>Int. J. Pharm.</source><year>2018</year><volume>535</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2017.10.046</pub-id><pub-id pub-id-type="pmid">29111097</pub-id>
</element-citation></ref><ref id="B9-pharmaceutics-17-00188"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patel</surname><given-names>B.A.</given-names></name>
</person-group><article-title>Permeation enhancement and advanced strategies: A comprehensive review of improved topical drug delivery</article-title><source>Int. Res. J. Mod. Eng. Technol. Sci.</source><year>2024</year><volume>6</volume><fpage>6691</fpage><lpage>6702</lpage></element-citation></ref><ref id="B10-pharmaceutics-17-00188"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goswami</surname><given-names>D.S.</given-names></name>
<name><surname>Uppal</surname><given-names>N.</given-names></name>
<name><surname>Goyal</surname><given-names>S.</given-names></name>
<name><surname>Mehta</surname><given-names>N.</given-names></name>
<name><surname>Gupta</surname><given-names>A.K.</given-names></name>
</person-group><article-title>Permeation enhancer for TDDS from natural and synthetic sources: A review</article-title><source>J. Biomed. Pharm. Res.</source><year>2013</year><volume>2</volume><fpage>19</fpage><lpage>29</lpage></element-citation></ref><ref id="B11-pharmaceutics-17-00188"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matharoo</surname><given-names>N.</given-names></name>
<name><surname>Mohd</surname><given-names>H.</given-names></name>
<name><surname>Michniak-Kohn</surname><given-names>B.</given-names></name>
</person-group><article-title>Transferosomes as a transdermal drug delivery system: Dermal kinetics and recent developments</article-title><source>Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.</source><year>2024</year><volume>16</volume><elocation-id>e1918</elocation-id><pub-id pub-id-type="doi">10.1002/wnan.1918</pub-id><pub-id pub-id-type="pmid">37527953</pub-id>
</element-citation></ref><ref id="B12-pharmaceutics-17-00188"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xue</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Mi</surname><given-names>X.</given-names></name>
<name><surname>Tan</surname><given-names>R.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Xiong</surname><given-names>R.</given-names></name>
<name><surname>Chen</surname><given-names>M.</given-names></name>
<name><surname>Tan</surname><given-names>W.-Q.</given-names></name>
</person-group><article-title>Transdermal drug delivery system: Current status and clinical application of microneedles</article-title><source>ACS Mater. Lett.</source><year>2024</year><volume>6</volume><fpage>801</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1021/acsmaterialslett.3c01317</pub-id></element-citation></ref><ref id="B13-pharmaceutics-17-00188"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ali</surname><given-names>R.</given-names></name>
<name><surname>Mehta</surname><given-names>P.</given-names></name>
<name><surname>Arshad</surname><given-names>M.</given-names></name>
<name><surname>Kucuk</surname><given-names>I.</given-names></name>
<name><surname>Chang</surname><given-names>M.</given-names></name>
<name><surname>Ahmad</surname><given-names>Z.</given-names></name>
</person-group><article-title>Transdermal microneedles&#x02014;A materials perspective</article-title><source>AAPS Pharmscitech</source><year>2020</year><volume>21</volume><fpage>12</fpage><pub-id pub-id-type="doi">10.1208/s12249-019-1560-3</pub-id><pub-id pub-id-type="pmid">31807980</pub-id>
</element-citation></ref><ref id="B14-pharmaceutics-17-00188"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Priya</surname><given-names>S.</given-names></name>
<name><surname>Singhvi</surname><given-names>G.</given-names></name>
</person-group><article-title>Microneedles-based drug delivery strategies: A breakthrough approach for the management of pain</article-title><source>Biomed. Pharmacother.</source><year>2022</year><volume>155</volume><elocation-id>113717</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2022.113717</pub-id><pub-id pub-id-type="pmid">36174381</pub-id>
</element-citation></ref><ref id="B15-pharmaceutics-17-00188"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van Der Maaden</surname><given-names>K.</given-names></name>
<name><surname>Jiskoot</surname><given-names>W.</given-names></name>
<name><surname>Bouwstra</surname><given-names>J.</given-names></name>
</person-group><article-title>Microneedle technologies for (trans) dermal drug and vaccine delivery</article-title><source>J. Control. Release</source><year>2012</year><volume>161</volume><fpage>645</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2012.01.042</pub-id><pub-id pub-id-type="pmid">22342643</pub-id>
</element-citation></ref><ref id="B16-pharmaceutics-17-00188"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bala</surname><given-names>P.</given-names></name>
<name><surname>Jathar</surname><given-names>S.</given-names></name>
<name><surname>Kale</surname><given-names>S.</given-names></name>
<name><surname>Pal</surname><given-names>K.</given-names></name>
</person-group><article-title>Transdermal drug delivery system (TDDS)-a multifaceted approach for drug delivery</article-title><source>J. Pharm. Res.</source><year>2014</year><volume>8</volume><fpage>1805</fpage><lpage>1835</lpage></element-citation></ref><ref id="B17-pharmaceutics-17-00188"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tran</surname><given-names>K.T.</given-names></name>
<name><surname>Gavitt</surname><given-names>T.D.</given-names></name>
<name><surname>Farrell</surname><given-names>N.J.</given-names></name>
<name><surname>Curry</surname><given-names>E.J.</given-names></name>
<name><surname>Mara</surname><given-names>A.B.</given-names></name>
<name><surname>Patel</surname><given-names>A.</given-names></name>
<name><surname>Brown</surname><given-names>L.</given-names></name>
<name><surname>Kilpatrick</surname><given-names>S.</given-names></name>
<name><surname>Piotrowska</surname><given-names>R.</given-names></name>
<name><surname>Mishra</surname><given-names>N.</given-names></name>
</person-group><article-title>Transdermal microneedles for the programmable burst release of multiple vaccine payloads</article-title><source>Nat. Biomed. Eng.</source><year>2021</year><volume>5</volume><fpage>998</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.1038/s41551-020-00650-4</pub-id><pub-id pub-id-type="pmid">33230304</pub-id>
</element-citation></ref><ref id="B18-pharmaceutics-17-00188"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yadav</surname><given-names>P.R.</given-names></name>
<name><surname>Munni</surname><given-names>M.N.</given-names></name>
<name><surname>Campbell</surname><given-names>L.</given-names></name>
<name><surname>Mostofa</surname><given-names>G.</given-names></name>
<name><surname>Dobson</surname><given-names>L.</given-names></name>
<name><surname>Shittu</surname><given-names>M.</given-names></name>
<name><surname>Pattanayek</surname><given-names>S.K.</given-names></name>
<name><surname>Uddin</surname><given-names>M.J.</given-names></name>
<name><surname>Das</surname><given-names>D.B.</given-names></name>
</person-group><article-title>Translation of polymeric microneedles for treatment of human diseases: Recent trends, Progress, and Challenges</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>1132</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13081132</pub-id><pub-id pub-id-type="pmid">34452093</pub-id>
</element-citation></ref><ref id="B19-pharmaceutics-17-00188"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>B.Z.</given-names></name>
<name><surname>Wang</surname><given-names>Q.L.</given-names></name>
<name><surname>Jin</surname><given-names>X.</given-names></name>
<name><surname>Guo</surname><given-names>X.D.</given-names></name>
</person-group><article-title>Fabrication of coated polymer microneedles for transdermal drug delivery</article-title><source>J. Control. Release</source><year>2017</year><volume>265</volume><fpage>14</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2017.03.383</pub-id><pub-id pub-id-type="pmid">28344014</pub-id>
</element-citation></ref><ref id="B20-pharmaceutics-17-00188"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alvi</surname><given-names>I.A.</given-names></name>
<name><surname>Madan</surname><given-names>J.</given-names></name>
<name><surname>Kaushik</surname><given-names>D.</given-names></name>
<name><surname>Sardana</surname><given-names>S.</given-names></name>
<name><surname>Pandey</surname><given-names>R.S.</given-names></name>
<name><surname>Ali</surname><given-names>A.</given-names></name>
</person-group><article-title>Comparative study of transfersomes, liposomes, and niosomes for topical delivery of 5-fluorouracil to skin cancer cells: Preparation, characterization, in-vitro release, and cytotoxicity analysis</article-title><source>Anti-Cancer Drugs</source><year>2011</year><volume>22</volume><fpage>774</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1097/CAD.0b013e328346c7d6</pub-id><pub-id pub-id-type="pmid">21799471</pub-id>
</element-citation></ref><ref id="B21-pharmaceutics-17-00188"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Parhi</surname><given-names>R.</given-names></name>
<name><surname>Mandru</surname><given-names>A.</given-names></name>
</person-group><article-title>Enhancement of skin permeability with thermal ablation techniques: Concept to commercial products</article-title><source>Drug Deliv. Transl. Res.</source><year>2021</year><volume>11</volume><fpage>817</fpage><lpage>841</lpage><pub-id pub-id-type="doi">10.1007/s13346-020-00823-3</pub-id><pub-id pub-id-type="pmid">32696221</pub-id>
</element-citation></ref><ref id="B22-pharmaceutics-17-00188"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bajwa</surname><given-names>M.N.</given-names></name>
<name><surname>Muta</surname><given-names>K.</given-names></name>
<name><surname>Malik</surname><given-names>M.I.</given-names></name>
<name><surname>Siddiqui</surname><given-names>S.A.</given-names></name>
<name><surname>Braun</surname><given-names>S.A.</given-names></name>
<name><surname>Homey</surname><given-names>B.</given-names></name>
<name><surname>Dengel</surname><given-names>A.</given-names></name>
<name><surname>Ahmed</surname><given-names>S.</given-names></name>
</person-group><article-title>Computer-aided diagnosis of skin diseases using deep neural networks</article-title><source>Appl. Sci.</source><year>2020</year><volume>10</volume><elocation-id>2488</elocation-id><pub-id pub-id-type="doi">10.3390/app10072488</pub-id></element-citation></ref><ref id="B23-pharmaceutics-17-00188"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Ye</surname><given-names>Z.</given-names></name>
<name><surname>Gao</surname><given-names>H.</given-names></name>
<name><surname>Ouyang</surname><given-names>D.</given-names></name>
</person-group><article-title>Computational pharmaceutics-A new paradigm of drug delivery</article-title><source>J. Control. Release</source><year>2021</year><volume>338</volume><fpage>119</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2021.08.030</pub-id><pub-id pub-id-type="pmid">34418520</pub-id>
</element-citation></ref><ref id="B24-pharmaceutics-17-00188"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tyagi</surname><given-names>S.</given-names></name>
<name><surname>Pathak</surname><given-names>A.</given-names></name>
<name><surname>Rao</surname><given-names>N.R.</given-names></name>
<name><surname>Nehra</surname><given-names>S.</given-names></name>
<name><surname>Asthana</surname><given-names>A.</given-names></name>
<name><surname>Sharma</surname><given-names>V.</given-names></name>
<name><surname>Katyal</surname><given-names>G.</given-names></name>
<name><surname>Bhardwaj</surname><given-names>A.</given-names></name>
<name><surname>Sharma</surname><given-names>L.</given-names></name>
<name><surname>Prakash</surname><given-names>S.</given-names></name>
</person-group><article-title>AI-assisted Formulation Design for Improved Drug Delivery and Bioavailability</article-title><source>Pak. Heart J.</source><year>2023</year><volume>56</volume><fpage>149</fpage><lpage>162</lpage></element-citation></ref><ref id="B25-pharmaceutics-17-00188"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hamet</surname><given-names>P.</given-names></name>
<name><surname>Tremblay</surname><given-names>J.</given-names></name>
</person-group><article-title>Artificial intelligence in medicine</article-title><source>Metabolism</source><year>2017</year><volume>69</volume><fpage>S36</fpage><lpage>S40</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2017.01.011</pub-id></element-citation></ref><ref id="B26-pharmaceutics-17-00188"><label>26.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Mech</surname><given-names>D.J.</given-names></name>
<name><surname>Murugappan</surname><given-names>S.</given-names></name>
<name><surname>Buddhiraju</surname><given-names>H.S.</given-names></name>
<name><surname>Eranki</surname><given-names>A.</given-names></name>
<name><surname>Rengan</surname><given-names>A.K.</given-names></name>
<name><surname>Rizvi</surname><given-names>M.S.</given-names></name>
</person-group><article-title>AI on DDS for regenerative medicine</article-title><source>Artificial Intelligence in Tissue and Organ Regeneration</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2023</year><fpage>133</fpage><lpage>153</lpage></element-citation></ref><ref id="B27-pharmaceutics-17-00188"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elder</surname><given-names>A.</given-names></name>
<name><surname>Cappelli</surname><given-names>M.O.D.</given-names></name>
<name><surname>Ring</surname><given-names>C.</given-names></name>
<name><surname>Saedi</surname><given-names>N.</given-names></name>
</person-group><article-title>Artificial intelligence in cosmetic dermatology: An update on current trends</article-title><source>Clin. Dermatol.</source><year>2024</year><volume>42</volume><fpage>216</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1016/j.clindermatol.2023.12.015</pub-id><pub-id pub-id-type="pmid">38181887</pub-id>
</element-citation></ref><ref id="B28-pharmaceutics-17-00188"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hassanzadeh</surname><given-names>P.</given-names></name>
<name><surname>Atyabi</surname><given-names>F.</given-names></name>
<name><surname>Dinarvand</surname><given-names>R.</given-names></name>
</person-group><article-title>The significance of artificial intelligence in drug delivery system design</article-title><source>Adv. Drug Deliv. Rev.</source><year>2019</year><volume>151</volume><fpage>169</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2019.05.001</pub-id><pub-id pub-id-type="pmid">31071378</pub-id>
</element-citation></ref><ref id="B29-pharmaceutics-17-00188"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dara</surname><given-names>S.</given-names></name>
<name><surname>Dhamercherla</surname><given-names>S.</given-names></name>
<name><surname>Jadav</surname><given-names>S.S.</given-names></name>
<name><surname>Babu</surname><given-names>C.M.</given-names></name>
<name><surname>Ahsan</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Machine learning in drug discovery: A review</article-title><source>Artif. Intell. Rev.</source><year>2022</year><volume>55</volume><fpage>1947</fpage><lpage>1999</lpage><pub-id pub-id-type="doi">10.1007/s10462-021-10058-4</pub-id><pub-id pub-id-type="pmid">34393317</pub-id>
</element-citation></ref><ref id="B30-pharmaceutics-17-00188"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vora</surname><given-names>L.K.</given-names></name>
<name><surname>Gholap</surname><given-names>A.D.</given-names></name>
<name><surname>Jetha</surname><given-names>K.</given-names></name>
<name><surname>Thakur</surname><given-names>R.R.S.</given-names></name>
<name><surname>Solanki</surname><given-names>H.K.</given-names></name>
<name><surname>Chavda</surname><given-names>V.P.</given-names></name>
</person-group><article-title>Artificial intelligence in pharmaceutical technology and drug delivery design</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>1916</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15071916</pub-id><pub-id pub-id-type="pmid">37514102</pub-id>
</element-citation></ref><ref id="B31-pharmaceutics-17-00188"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Antontsev</surname><given-names>V.</given-names></name>
<name><surname>Jagarapu</surname><given-names>A.</given-names></name>
<name><surname>Bundey</surname><given-names>Y.</given-names></name>
<name><surname>Hou</surname><given-names>H.</given-names></name>
<name><surname>Khotimchenko</surname><given-names>M.</given-names></name>
<name><surname>Walsh</surname><given-names>J.</given-names></name>
<name><surname>Varshney</surname><given-names>J.</given-names></name>
</person-group><article-title>A hybrid modeling approach for assessing mechanistic models of small molecule partitioning in vivo using a machine learning-integrated modeling platform</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><elocation-id>11143</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-021-90637-1</pub-id><pub-id pub-id-type="pmid">34045592</pub-id>
</element-citation></ref><ref id="B32-pharmaceutics-17-00188"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>LaCount</surname><given-names>T.D.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Hao</surname><given-names>J.</given-names></name>
<name><surname>Ghosh</surname><given-names>P.</given-names></name>
<name><surname>Raney</surname><given-names>S.G.</given-names></name>
<name><surname>Talattof</surname><given-names>A.</given-names></name>
<name><surname>Kasting</surname><given-names>G.B.</given-names></name>
<name><surname>Li</surname><given-names>S.K.</given-names></name>
</person-group><article-title>Modeling temperature-dependent dermal absorption and clearance for transdermal and topical drug applications</article-title><source>AAPS J.</source><year>2020</year><volume>22</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1208/s12248-020-00451-2</pub-id><pub-id pub-id-type="pmid">32390069</pub-id>
</element-citation></ref><ref id="B33-pharmaceutics-17-00188"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shanbehzadeh</surname><given-names>M.</given-names></name>
<name><surname>Nopour</surname><given-names>R.</given-names></name>
<name><surname>Kazemi-Arpanahi</surname><given-names>H.</given-names></name>
</person-group><article-title>Developing an artificial neural network for detecting COVID-19 disease</article-title><source>J. Educ. Health Promot.</source><year>2022</year><volume>11</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.4103/jehp.jehp_387_21</pub-id><pub-id pub-id-type="pmid">35281397</pub-id>
</element-citation></ref><ref id="B34-pharmaceutics-17-00188"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Tian</surname><given-names>Y.</given-names></name>
<name><surname>Qin</surname><given-names>Z.</given-names></name>
<name><surname>Yan</surname><given-names>A.</given-names></name>
</person-group><article-title>Classification of HIV-1 protease inhibitors by machine learning methods</article-title><source>ACS Omega</source><year>2018</year><volume>3</volume><fpage>15837</fpage><lpage>15849</lpage><pub-id pub-id-type="doi">10.1021/acsomega.8b01843</pub-id><pub-id pub-id-type="pmid">30556015</pub-id>
</element-citation></ref><ref id="B35-pharmaceutics-17-00188"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>F.-Y.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Huang</surname><given-names>Y.-Y.</given-names></name>
<name><surname>Cheng</surname><given-names>C.-M.</given-names></name>
</person-group><article-title>Transdermal drug delivery systems for fighting common viral infectious diseases</article-title><source>Drug Deliv. Transl. Res.</source><year>2021</year><volume>11</volume><fpage>1498</fpage><lpage>1508</lpage><pub-id pub-id-type="doi">10.1007/s13346-021-01004-6</pub-id><pub-id pub-id-type="pmid">34024014</pub-id>
</element-citation></ref><ref id="B36-pharmaceutics-17-00188"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Joshi</surname><given-names>N.</given-names></name>
<name><surname>Machekposhti</surname><given-names>S.A.</given-names></name>
<name><surname>Narayan</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Evolution of transdermal drug delivery devices and novel microneedle technologies: A historical perspective and review</article-title><source>JID Innov.</source><year>2023</year><volume>3</volume><fpage>100225</fpage><pub-id pub-id-type="doi">10.1016/j.xjidi.2023.100225</pub-id><pub-id pub-id-type="pmid">37744689</pub-id>
</element-citation></ref><ref id="B37-pharmaceutics-17-00188"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Whitley</surname><given-names>R.J.</given-names></name>
<name><surname>Roizman</surname><given-names>B.</given-names></name>
</person-group><article-title>Herpes simplex virus infections</article-title><source>Lancet</source><year>2001</year><volume>357</volume><fpage>1513</fpage><lpage>1518</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)04638-9</pub-id><pub-id pub-id-type="pmid">11377626</pub-id>
</element-citation></ref><ref id="B38-pharmaceutics-17-00188"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Konicke</surname><given-names>K.</given-names></name>
<name><surname>Olasz</surname><given-names>E.</given-names></name>
</person-group><article-title>Successful treatment of recalcitrant plantar warts with bleomycin and microneedling</article-title><source>Dermatol. Surg.</source><year>2016</year><volume>42</volume><fpage>1007</fpage><lpage>1008</lpage><pub-id pub-id-type="doi">10.1097/DSS.0000000000000738</pub-id><pub-id pub-id-type="pmid">27227479</pub-id>
</element-citation></ref><ref id="B39-pharmaceutics-17-00188"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alshehri</surname><given-names>S.</given-names></name>
<name><surname>Hussain</surname><given-names>A.</given-names></name>
<name><surname>Altamimi</surname><given-names>M.A.</given-names></name>
<name><surname>Ramzan</surname><given-names>M.</given-names></name>
</person-group><article-title>In vitro, ex vivo, and in vivo studies of binary ethosomes for transdermal delivery of acyclovir: A comparative assessment</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2021</year><volume>62</volume><fpage>102390</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2021.102390</pub-id></element-citation></ref><ref id="B40-pharmaceutics-17-00188"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghonemy</surname><given-names>S.</given-names></name>
<name><surname>Ibrahim Ali</surname><given-names>M.</given-names></name>
<name><surname>Ebrahim</surname><given-names>H.M.</given-names></name>
</person-group><article-title>The efficacy of microneedling alone vs its combination with 5-fluorouracil solution vs 5-fluorouracil intralesional injection in the treatment of plantar warts</article-title><source>Dermatol. Ther.</source><year>2020</year><volume>33</volume><fpage>e14179</fpage><pub-id pub-id-type="doi">10.1111/dth.14179</pub-id><pub-id pub-id-type="pmid">32785986</pub-id>
</element-citation></ref><ref id="B41-pharmaceutics-17-00188"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Xiu</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Su</surname><given-names>R.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Ma</surname><given-names>S.</given-names></name>
<name><surname>Ma</surname><given-names>F.</given-names></name>
</person-group><article-title>Coated Porous Microneedles for Effective Intradermal Immunization with Split Influenza Vaccine</article-title><source>ACS Biomater. Sci. Eng.</source><year>2023</year><volume>9</volume><fpage>6880</fpage><lpage>6890</lpage><pub-id pub-id-type="doi">10.1021/acsbiomaterials.3c01212</pub-id><pub-id pub-id-type="pmid">37967566</pub-id>
</element-citation></ref><ref id="B42-pharmaceutics-17-00188"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>E.</given-names></name>
<name><surname>Erdos</surname><given-names>G.</given-names></name>
<name><surname>Huang</surname><given-names>S.</given-names></name>
<name><surname>Kenniston</surname><given-names>T.W.</given-names></name>
<name><surname>Balmert</surname><given-names>S.C.</given-names></name>
<name><surname>Carey</surname><given-names>C.D.</given-names></name>
<name><surname>Raj</surname><given-names>V.S.</given-names></name>
<name><surname>Epperly</surname><given-names>M.W.</given-names></name>
<name><surname>Klimstra</surname><given-names>W.B.</given-names></name>
<name><surname>Haagmans</surname><given-names>B.L.</given-names></name>
<etal/>
</person-group><article-title>Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development</article-title><source>EBioMedicine</source><year>2020</year><volume>55</volume><elocation-id>102743</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2020.102743</pub-id><pub-id pub-id-type="pmid">32249203</pub-id>
</element-citation></ref><ref id="B43-pharmaceutics-17-00188"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>da Silva Meira</surname><given-names>A.</given-names></name>
<name><surname>Battistel</surname><given-names>A.P.</given-names></name>
<name><surname>Teixeira</surname><given-names>H.F.</given-names></name>
<name><surname>Volpato</surname><given-names>N.M.</given-names></name>
</person-group><article-title>Development of nanoemulsions containing penciclovir for herpes simplex treatment and a liquid chromatographic method to drug assessment in porcine skin layers</article-title><source>Drug Anal. Res.</source><year>2020</year><volume>4</volume><fpage>22</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.22456/2527-2616.103121</pub-id></element-citation></ref><ref id="B44-pharmaceutics-17-00188"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaur</surname><given-names>A.</given-names></name>
<name><surname>Sharma</surname><given-names>G.</given-names></name>
<name><surname>Gupta</surname><given-names>V.</given-names></name>
<name><surname>Ratho</surname><given-names>R.K.</given-names></name>
<name><surname>Shishu</surname></name>
<name><surname>Katare</surname><given-names>O.P.</given-names></name>
</person-group><article-title>Enhanced acyclovir delivery using w/o type microemulsion: Preclinical assessment of antiviral activity using murine model of zosteriform cutaneous HSV-1 infection</article-title><source>Artif. Cells Nanomed. Biotechnol.</source><year>2018</year><volume>46</volume><fpage>346</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1080/21691401.2017.1313262</pub-id><pub-id pub-id-type="pmid">28403666</pub-id>
</element-citation></ref><ref id="B45-pharmaceutics-17-00188"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kang</surname><given-names>G.</given-names></name>
<name><surname>Kim</surname><given-names>M.</given-names></name>
<name><surname>Lee</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name>
<name><surname>Seong</surname><given-names>B.-L.</given-names></name>
<name><surname>Jung</surname><given-names>H.</given-names></name>
</person-group><article-title>Egg microneedles for transdermal vaccination of inactivated influenza virus</article-title><source>Biomater. Sci.</source><year>2024</year><volume>12</volume><fpage>907</fpage><lpage>918</lpage><pub-id pub-id-type="doi">10.1039/D3BM01635H</pub-id><pub-id pub-id-type="pmid">38174731</pub-id>
</element-citation></ref><ref id="B46-pharmaceutics-17-00188"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reyna</surname><given-names>D.</given-names></name>
<name><surname>Bejster</surname><given-names>I.</given-names></name>
<name><surname>Chadderdon</surname><given-names>A.</given-names></name>
<name><surname>Harteg</surname><given-names>C.</given-names></name>
<name><surname>Anjani</surname><given-names>Q.K.</given-names></name>
<name><surname>Bin Sabri</surname><given-names>A.H.</given-names></name>
<name><surname>Brown</surname><given-names>A.N.</given-names></name>
<name><surname>Drusano</surname><given-names>G.L.</given-names></name>
<name><surname>Westover</surname><given-names>J.</given-names></name>
<name><surname>Tarbet</surname><given-names>E.B.</given-names></name>
<etal/>
</person-group><article-title>A five-day treatment course of zanamivir for the flu with a single, self-administered, painless microneedle array patch: Revolutionizing delivery of poorly membrane-permeable therapeutics</article-title><source>Int. J. Pharm.</source><year>2023</year><volume>641</volume><fpage>123081</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2023.123081</pub-id><pub-id pub-id-type="pmid">37230371</pub-id>
</element-citation></ref><ref id="B47-pharmaceutics-17-00188"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sinani</surname><given-names>G.</given-names></name>
<name><surname>Sessevmez</surname><given-names>M.</given-names></name>
<name><surname>&#x0015e;enel</surname><given-names>S.</given-names></name>
</person-group><article-title>Applications of chitosan in prevention and treatment strategies of infectious diseases</article-title><source>Pharmaceutics</source><year>2024</year><volume>16</volume><elocation-id>1201</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics16091201</pub-id><pub-id pub-id-type="pmid">39339237</pub-id>
</element-citation></ref><ref id="B48-pharmaceutics-17-00188"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shan</surname><given-names>S.</given-names></name>
<name><surname>Hu</surname><given-names>J.</given-names></name>
<name><surname>Zheng</surname><given-names>Z.</given-names></name>
<name><surname>Gui</surname><given-names>S.</given-names></name>
<name><surname>Long</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>D.</given-names></name>
<name><surname>He</surname><given-names>N.</given-names></name>
</person-group><article-title>DevelopmentandAssessmentofAcyclovirGelPlasterContainingSpongeSpicules</article-title><source>J. Pharm.</source><year>2023</year><volume>12</volume><fpage>2879</fpage><lpage>2890</lpage></element-citation></ref><ref id="B49-pharmaceutics-17-00188"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kennedy</surname><given-names>G.M.</given-names></name>
<name><surname>Lhatoo</surname><given-names>S.D.</given-names></name>
</person-group><article-title>CNS adverse events associated with antiepileptic drugs</article-title><source>CNS Drugs</source><year>2008</year><volume>22</volume><fpage>739</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.2165/00023210-200822090-00003</pub-id><pub-id pub-id-type="pmid">18698874</pub-id>
</element-citation></ref><ref id="B50-pharmaceutics-17-00188"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Gage</surname><given-names>S.B.</given-names></name>
<name><surname>B&#x000e9;gaud</surname><given-names>B.</given-names></name>
<name><surname>Bazin</surname><given-names>F.</given-names></name>
<name><surname>Verdoux</surname><given-names>H.</given-names></name>
<name><surname>Dartigues</surname><given-names>J.-F.</given-names></name>
<name><surname>P&#x000e9;r&#x000e8;s</surname><given-names>K.</given-names></name>
<name><surname>Kurth</surname><given-names>T.</given-names></name>
<name><surname>Pariente</surname><given-names>A.</given-names></name>
</person-group><article-title>Benzodiazepine use and risk of dementia: Prospective population based study</article-title><source>BMJ</source><year>2012</year><volume>345</volume><fpage>6231</fpage><pub-id pub-id-type="doi">10.1136/bmj.e6231</pub-id></element-citation></ref><ref id="B51-pharmaceutics-17-00188"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rezvani</surname><given-names>A.H.</given-names></name>
<name><surname>Levin</surname><given-names>E.D.</given-names></name>
</person-group><article-title>Cognitive effects of nicotine</article-title><source>Biol. Psychiatry</source><year>2001</year><volume>49</volume><fpage>258</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1016/S0006-3223(00)01094-5</pub-id><pub-id pub-id-type="pmid">11230877</pub-id>
</element-citation></ref><ref id="B52-pharmaceutics-17-00188"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Quik</surname><given-names>M.</given-names></name>
</person-group><article-title>Smoking, nicotine and Parkinson&#x02019;s disease</article-title><source>Trends Neurosci.</source><year>2004</year><volume>27</volume><fpage>561</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2004.06.008</pub-id><pub-id pub-id-type="pmid">15331239</pub-id>
</element-citation></ref><ref id="B53-pharmaceutics-17-00188"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>N.</given-names></name>
<name><surname>Pillay</surname><given-names>V.</given-names></name>
<name><surname>Choonara</surname><given-names>Y.E.</given-names></name>
</person-group><article-title>Advances in the treatment of Parkinson&#x02019;s disease</article-title><source>Progress Neurobiol.</source><year>2007</year><volume>81</volume><fpage>29</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.pneurobio.2006.11.009</pub-id></element-citation></ref><ref id="B54-pharmaceutics-17-00188"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amsterdam</surname><given-names>J.D.</given-names></name>
</person-group><article-title>A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder</article-title><source>J. Clin. Psychiatry</source><year>2003</year><volume>64</volume><fpage>208</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.4088/JCP.v64n0216</pub-id><pub-id pub-id-type="pmid">12633131</pub-id>
</element-citation></ref><ref id="B55-pharmaceutics-17-00188"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Indermun</surname><given-names>S.</given-names></name>
<name><surname>Luttge</surname><given-names>R.</given-names></name>
<name><surname>Choonara</surname><given-names>Y.E.</given-names></name>
<name><surname>Kumar</surname><given-names>P.</given-names></name>
<name><surname>Du Toit</surname><given-names>L.C.</given-names></name>
<name><surname>Modi</surname><given-names>G.</given-names></name>
<name><surname>Pillay</surname><given-names>V.</given-names></name>
</person-group><article-title>Current advances in the fabrication of microneedles for transdermal delivery</article-title><source>J. Control. Release</source><year>2014</year><volume>185</volume><fpage>130</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2014.04.052</pub-id><pub-id pub-id-type="pmid">24806483</pub-id>
</element-citation></ref><ref id="B56-pharmaceutics-17-00188"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>M&#x000f6;ller</surname><given-names>H.-J.</given-names></name>
<name><surname>Hampel</surname><given-names>H.</given-names></name>
<name><surname>Hegerl</surname><given-names>U.</given-names></name>
<name><surname>Schmitt</surname><given-names>W.</given-names></name>
<name><surname>Walter</surname><given-names>K.</given-names></name>
</person-group><article-title>Double-blind, randomized, placebo-controlled clinical trial on the efficacy and tolerability of a physostigmine patch in patients with senile dementia of the Alzheimer type</article-title><source>Pharmacopsychiatry</source><year>1999</year><volume>32</volume><fpage>99</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1055/s-2007-979202</pub-id><pub-id pub-id-type="pmid">10463377</pub-id>
</element-citation></ref><ref id="B57-pharmaceutics-17-00188"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jaskari</surname><given-names>T.</given-names></name>
<name><surname>Vuorio</surname><given-names>M.</given-names></name>
<name><surname>Kontturi</surname><given-names>K.</given-names></name>
<name><surname>Urtti</surname><given-names>A.</given-names></name>
<name><surname>Manzanares</surname><given-names>J.A.</given-names></name>
<name><surname>Hirvonen</surname><given-names>J.</given-names></name>
</person-group><article-title>Controlled transdermal iontophoresis by ion-exchange fiber</article-title><source>J. Control. Release</source><year>2000</year><volume>67</volume><fpage>179</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1016/S0168-3659(00)00204-2</pub-id><pub-id pub-id-type="pmid">10825552</pub-id>
</element-citation></ref><ref id="B58-pharmaceutics-17-00188"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Winblad</surname><given-names>B.</given-names></name>
<name><surname>Cummings</surname><given-names>J.</given-names></name>
<name><surname>Andreasen</surname><given-names>N.</given-names></name>
<name><surname>Grossberg</surname><given-names>G.</given-names></name>
<name><surname>Onofrj</surname><given-names>M.</given-names></name>
<name><surname>Sadowsky</surname><given-names>C.</given-names></name>
<name><surname>Zechner</surname><given-names>S.</given-names></name>
<name><surname>Nagel</surname><given-names>J.</given-names></name>
<name><surname>Lane</surname><given-names>R.</given-names></name>
</person-group><article-title>A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer&#x02019;s disease&#x02013;&#x02013;rivastigmine patch versus capsule</article-title><source>Int. J. Geriatr. Psychiatry A J. Psychiatry Late Life Allied Sci.</source><year>2007</year><volume>22</volume><fpage>456</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1002/gps.1788</pub-id></element-citation></ref><ref id="B59-pharmaceutics-17-00188"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kamsani</surname><given-names>N.H.</given-names></name>
<name><surname>Hasan</surname><given-names>M.S.</given-names></name>
<name><surname>Rullah</surname><given-names>K.</given-names></name>
<name><surname>Haris</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Nicotine-Loaded Polyvinyl Alcohol Electrospun Nanofibers as Transdermal Patches for Smoking Cessation: Formulation and Characterization</article-title><source>Pharm. Chem. J.</source><year>2024</year><volume>57</volume><fpage>1637</fpage><lpage>1646</lpage><pub-id pub-id-type="doi">10.1007/s11094-024-03059-4</pub-id></element-citation></ref><ref id="B60-pharmaceutics-17-00188"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Levy</surname><given-names>A.</given-names></name>
<name><surname>Brandeis</surname><given-names>R.</given-names></name>
<name><surname>Treves</surname><given-names>T.</given-names></name>
<name><surname>Meshulam</surname><given-names>Y.</given-names></name>
<name><surname>Mawassi</surname><given-names>F.</given-names></name>
<name><surname>Feiler</surname><given-names>D.</given-names></name>
<name><surname>Wengier</surname><given-names>A.</given-names></name>
<name><surname>Glikfeld</surname><given-names>P.</given-names></name>
<name><surname>Grunwald</surname><given-names>J.</given-names></name>
<name><surname>Dachir</surname><given-names>S.</given-names></name>
</person-group><article-title>Transdermal physostigmine in the treatment of Alzheimer&#x02019;s disease</article-title><source>Alzheimer Dis. Assoc. Disord.</source><year>1994</year><volume>8</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1097/00002093-199408010-00004</pub-id><pub-id pub-id-type="pmid">8185877</pub-id>
</element-citation></ref><ref id="B61-pharmaceutics-17-00188"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Walter</surname><given-names>K.</given-names></name>
<name><surname>Muller</surname><given-names>M.</given-names></name>
<name><surname>Barkworth</surname><given-names>M.</given-names></name>
<name><surname>Nieciecki</surname><given-names>A.</given-names></name>
<name><surname>Stanislaus</surname><given-names>F.</given-names></name>
</person-group><article-title>Pharmacokinetics of physostigmine in man following a single application of a transdermal system</article-title><source>Br. J. Clin. Pharmacol.</source><year>1995</year><volume>39</volume><fpage>59</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.1995.tb04410.x</pub-id><pub-id pub-id-type="pmid">7756100</pub-id>
</element-citation></ref><ref id="B62-pharmaceutics-17-00188"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Utsuki</surname><given-names>T.</given-names></name>
<name><surname>Uchimura</surname><given-names>N.</given-names></name>
<name><surname>Irikura</surname><given-names>M.</given-names></name>
<name><surname>Moriuchi</surname><given-names>H.</given-names></name>
<name><surname>Holloway</surname><given-names>H.W.</given-names></name>
<name><surname>Yu</surname><given-names>Q.-S.</given-names></name>
<name><surname>Spangler</surname><given-names>E.L.</given-names></name>
<name><surname>Mamczarz</surname><given-names>J.</given-names></name>
<name><surname>Ingram</surname><given-names>D.K.</given-names></name>
<name><surname>Irie</surname><given-names>T.</given-names></name>
</person-group><article-title>Preclinical investigation of the topical administration of phenserine: Transdermal flux, cholinesterase inhibition, and cognitive efficacy</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2007</year><volume>321</volume><fpage>353</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1124/jpet.106.118000</pub-id><pub-id pub-id-type="pmid">17255466</pub-id>
</element-citation></ref><ref id="B63-pharmaceutics-17-00188"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sadeghi</surname><given-names>M.</given-names></name>
<name><surname>Ganji</surname><given-names>F.</given-names></name>
<name><surname>Taghizadeh</surname><given-names>S.M.</given-names></name>
<name><surname>Daraei</surname><given-names>B.</given-names></name>
</person-group><article-title>Preparation and characterization of rivastigmine transdermal patch based on chitosan microparticles</article-title><source>Iran. J. Pharm. Res. IJPR</source><year>2016</year><volume>15</volume><fpage>283</fpage><pub-id pub-id-type="pmid">28479923</pub-id>
</element-citation></ref><ref id="B64-pharmaceutics-17-00188"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patel</surname><given-names>N.</given-names></name>
<name><surname>Jain</surname><given-names>S.</given-names></name>
<name><surname>Madan</surname><given-names>P.</given-names></name>
<name><surname>Lin</surname><given-names>S.</given-names></name>
</person-group><article-title>Influence of electronic and formulation variables on transdermal iontophoresis of tacrine hydrochloride</article-title><source>Pharm. Dev. Technol.</source><year>2015</year><volume>20</volume><fpage>442</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.3109/10837450.2013.879886</pub-id><pub-id pub-id-type="pmid">24467234</pub-id>
</element-citation></ref><ref id="B65-pharmaceutics-17-00188"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rapoport</surname><given-names>A.M.</given-names></name>
<name><surname>Freitag</surname><given-names>F.</given-names></name>
<name><surname>Pearlman</surname><given-names>S.H.</given-names></name>
</person-group><article-title>Innovative delivery systems for migraine: The clinical utility of a transdermal patch for the acute treatment of migraine</article-title><source>CNS Drugs</source><year>2010</year><volume>24</volume><fpage>929</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.2165/11317540-000000000-00000</pub-id><pub-id pub-id-type="pmid">20932065</pub-id>
</element-citation></ref><ref id="B66-pharmaceutics-17-00188"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Yu</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>P.</given-names></name>
<name><surname>Ma</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Xu</surname><given-names>H.</given-names></name>
<name><surname>Sui</surname><given-names>D.</given-names></name>
</person-group><article-title>Neuroprotective effects of pramipexole transdermal patch in the MPTP-induced mouse model of Parkinson&#x02019;s disease</article-title><source>J. Pharmacol. Sci.</source><year>2018</year><volume>138</volume><fpage>31</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.jphs.2018.08.008</pub-id><pub-id pub-id-type="pmid">30241783</pub-id>
</element-citation></ref><ref id="B67-pharmaceutics-17-00188"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Larkin</surname><given-names>H.D.</given-names></name>
</person-group><article-title>First donepezil transdermal patch approved for Alzheimer disease</article-title><source>JAMA</source><year>2022</year><volume>327</volume><fpage>1642</fpage><pub-id pub-id-type="doi">10.1001/jama.2022.6662</pub-id></element-citation></ref><ref id="B68-pharmaceutics-17-00188"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Raeder</surname><given-names>V.</given-names></name>
<name><surname>Boura</surname><given-names>I.</given-names></name>
<name><surname>Leta</surname><given-names>V.</given-names></name>
<name><surname>Jenner</surname><given-names>P.</given-names></name>
<name><surname>Reichmann</surname><given-names>H.</given-names></name>
<name><surname>Trenkwalder</surname><given-names>C.</given-names></name>
<name><surname>Klingelhoefer</surname><given-names>L.</given-names></name>
<name><surname>Chaudhuri</surname><given-names>K.R.</given-names></name>
</person-group><article-title>Rotigotine transdermal patch for motor and non-motor Parkinson&#x02019;s disease: A review of 12 years&#x02019; clinical experience</article-title><source>CNS Drugs</source><year>2021</year><volume>35</volume><fpage>215</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1007/s40263-020-00788-4</pub-id><pub-id pub-id-type="pmid">33559846</pub-id>
</element-citation></ref><ref id="B69-pharmaceutics-17-00188"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Song</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>N.</given-names></name>
<name><surname>Ren</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
</person-group><article-title>Tip-concentrated microneedle patch delivering everolimus for therapy of multiple sclerosis</article-title><source>Biomater. Adv.</source><year>2022</year><volume>135</volume><elocation-id>212729</elocation-id><pub-id pub-id-type="doi">10.1016/j.bioadv.2022.212729</pub-id><pub-id pub-id-type="pmid">35929200</pub-id>
</element-citation></ref><ref id="B70-pharmaceutics-17-00188"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Verana</surname><given-names>G.</given-names></name>
<name><surname>Tijani</surname><given-names>A.O.</given-names></name>
<name><surname>Puri</surname><given-names>A.</given-names></name>
</person-group><article-title>Nanosuspension-based microneedle skin patch of baclofen for sustained management of multiple sclerosis-related spasticity</article-title><source>Int. J. Pharm.</source><year>2023</year><volume>644</volume><fpage>123352</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2023.123352</pub-id><pub-id pub-id-type="pmid">37647979</pub-id>
</element-citation></ref><ref id="B71-pharmaceutics-17-00188"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>M.</given-names></name>
<name><surname>Derakhshanian</surname><given-names>S.</given-names></name>
<name><surname>Rath</surname><given-names>A.</given-names></name>
<name><surname>Bertrand</surname><given-names>S.</given-names></name>
<name><surname>DeGraw</surname><given-names>C.</given-names></name>
<name><surname>Barlow</surname><given-names>R.</given-names></name>
<name><surname>Menard</surname><given-names>A.</given-names></name>
<name><surname>Kaye</surname><given-names>A.M.</given-names></name>
<name><surname>Hasoon</surname><given-names>J.</given-names></name>
<name><surname>Cornett</surname><given-names>E.M.</given-names></name>
</person-group><article-title>Asenapine transdermal patch for the management of schizophrenia</article-title><source>Psychopharmacol. Bull.</source><year>2020</year><volume>50</volume><fpage>60</fpage><pub-id pub-id-type="pmid">33012873</pub-id>
</element-citation></ref><ref id="B72-pharmaceutics-17-00188"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Iwata</surname><given-names>N.</given-names></name>
<name><surname>Ishigooka</surname><given-names>J.</given-names></name>
<name><surname>Kim</surname><given-names>W.-H.</given-names></name>
<name><surname>Yoon</surname><given-names>B.-H.</given-names></name>
<name><surname>Lin</surname><given-names>S.-K.</given-names></name>
<name><surname>Sulaiman</surname><given-names>A.H.</given-names></name>
<name><surname>Cosca</surname><given-names>R.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Suchkov</surname><given-names>Y.</given-names></name>
<name><surname>Agarkov</surname><given-names>A.</given-names></name>
</person-group><article-title>Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study</article-title><source>Schizophr. Res.</source><year>2020</year><volume>215</volume><fpage>408</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2019.07.055</pub-id><pub-id pub-id-type="pmid">31471246</pub-id>
</element-citation></ref><ref id="B73-pharmaceutics-17-00188"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shafaat</surname><given-names>K.</given-names></name>
<name><surname>Kumar</surname><given-names>B.</given-names></name>
<name><surname>Das</surname><given-names>S.K.</given-names></name>
<name><surname>Ul Hasan</surname><given-names>R.</given-names></name>
<name><surname>Prajapati</surname><given-names>S.</given-names></name>
</person-group><article-title>Novel nanoemulsion as vehicles for transdermal delivery of Clozapine: In vitro and in vivo studies</article-title><source>Int. J. Pharm. Pharm. Sci.</source><year>2013</year><volume>5</volume><issue>(Suppl. S3)</issue><fpage>126</fpage><lpage>134</lpage></element-citation></ref><ref id="B74-pharmaceutics-17-00188"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Das</surname><given-names>B.</given-names></name>
<name><surname>Sen</surname><given-names>S.O.</given-names></name>
<name><surname>Maji</surname><given-names>R.</given-names></name>
<name><surname>Nayak</surname><given-names>A.K.</given-names></name>
<name><surname>Sen</surname><given-names>K.K.</given-names></name>
</person-group><article-title>Transferosomal gel for transdermal delivery of risperidone: Formulation optimization and ex vivo permeation</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2017</year><volume>38</volume><fpage>59</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.jddst.2017.01.006</pub-id></element-citation></ref><ref id="B75-pharmaceutics-17-00188"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Babu</surname><given-names>M.K.</given-names></name>
<name><surname>Sireesha</surname><given-names>R.</given-names></name>
<name><surname>Mounica</surname><given-names>N.</given-names></name>
<name><surname>Divya</surname><given-names>K.</given-names></name>
<name><surname>Hemprasad</surname><given-names>M.</given-names></name>
</person-group><article-title>Design and characterization of olanzapine transfersomes for percutaneous administration</article-title><source>Indian J. Res. Pharm. Biotechnol.</source><year>2015</year><volume>3</volume><elocation-id>151</elocation-id></element-citation></ref><ref id="B76-pharmaceutics-17-00188"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patel</surname><given-names>H.K.</given-names></name>
<name><surname>Shah</surname><given-names>C.V.</given-names></name>
<name><surname>Shah</surname><given-names>V.H.</given-names></name>
<name><surname>Upadhyay</surname><given-names>U.M.</given-names></name>
</person-group><article-title>Design, development and in vitro evaluation OF controlled release gel for topical delivery of quetiapine using box-behnken design</article-title><source>Int. J. Pharm. Sci. Res.</source><year>2012</year><volume>3</volume><fpage>3384</fpage></element-citation></ref><ref id="B77-pharmaceutics-17-00188"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ogawa</surname><given-names>R.</given-names></name>
<name><surname>Stachnik</surname><given-names>J.M.</given-names></name>
<name><surname>Echizen</surname><given-names>H.</given-names></name>
</person-group><article-title>Clinical pharmacokinetics of drugs in patients with heart failure: An update (part 1, drugs administered intravenously)</article-title><source>Clin. Pharmacokinet.</source><year>2013</year><volume>52</volume><fpage>169</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1007/s40262-012-0029-2</pub-id><pub-id pub-id-type="pmid">23344981</pub-id>
</element-citation></ref><ref id="B78-pharmaceutics-17-00188"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lainscak</surname><given-names>M.</given-names></name>
<name><surname>Vitale</surname><given-names>C.</given-names></name>
<name><surname>Seferovic</surname><given-names>P.</given-names></name>
<name><surname>Spoletini</surname><given-names>I.</given-names></name>
<name><surname>Trobec</surname><given-names>K.C.</given-names></name>
<name><surname>Rosano</surname><given-names>G.M.</given-names></name>
</person-group><article-title>Pharmacokinetics and pharmacodynamics of cardiovascular drugs in chronic heart failure</article-title><source>Int. J. Cardiol.</source><year>2016</year><volume>224</volume><fpage>191</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2016.09.015</pub-id><pub-id pub-id-type="pmid">27657473</pub-id>
</element-citation></ref><ref id="B79-pharmaceutics-17-00188"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mangoni</surname><given-names>A.A.</given-names></name>
<name><surname>Jarmuzewska</surname><given-names>E.A.</given-names></name>
</person-group><article-title>The influence of heart failure on the pharmacokinetics of cardiovascular and non-cardiovascular drugs: A critical appraisal of the evidence</article-title><source>Br. J. Clin. Pharmacol.</source><year>2019</year><volume>85</volume><fpage>20</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1111/bcp.13760</pub-id><pub-id pub-id-type="pmid">30194701</pub-id>
</element-citation></ref><ref id="B80-pharmaceutics-17-00188"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ahad</surname><given-names>A.</given-names></name>
<name><surname>Aqil</surname><given-names>M.</given-names></name>
<name><surname>Kohli</surname><given-names>K.</given-names></name>
<name><surname>Sultana</surname><given-names>Y.</given-names></name>
<name><surname>Mujeeb</surname><given-names>M.</given-names></name>
<name><surname>Ali</surname><given-names>A.</given-names></name>
</person-group><article-title>Interactions between novel terpenes and main components of rat and human skin: Mechanistic view for transdermal delivery of propranolol hydrochloride</article-title><source>Curr. Drug Deliv.</source><year>2011</year><volume>8</volume><fpage>213</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.2174/156720111794479907</pub-id><pub-id pub-id-type="pmid">21235472</pub-id>
</element-citation></ref><ref id="B81-pharmaceutics-17-00188"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Corbo</surname><given-names>M.</given-names></name>
<name><surname>Liu</surname><given-names>J.-C.</given-names></name>
<name><surname>Chien</surname><given-names>Y.W.</given-names></name>
</person-group><article-title>Bioavailability of propranolol following oral and transdermal administration in rabbits</article-title><source>J. Pharm. Sci.</source><year>1990</year><volume>79</volume><fpage>584</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1002/jps.2600790707</pub-id><pub-id pub-id-type="pmid">2398465</pub-id>
</element-citation></ref><ref id="B82-pharmaceutics-17-00188"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alwossabi</surname><given-names>A.M.</given-names></name>
<name><surname>Albegali</surname><given-names>A.A.</given-names></name>
<name><surname>Al-Ghani</surname><given-names>A.M.</given-names></name>
<name><surname>Albaser</surname><given-names>N.A.</given-names></name>
<name><surname>Alnamer</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Advancements in Transdermal Drug Delivery Systems: Innovations, Applications, and Future Directions</article-title><source>Al-Razi Univ. J. Med. Sci.</source><year>2024</year><fpage>1</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.51610/rujms8.2.2024.226</pub-id></element-citation></ref><ref id="B83-pharmaceutics-17-00188"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marsh</surname><given-names>N.</given-names></name>
<name><surname>Marsh</surname><given-names>A.</given-names></name>
</person-group><article-title>A short history of nitroglycerine and nitric oxide in pharmacology and physiology</article-title><source>Clin. Exp. Pharmacol. Physiol.</source><year>2000</year><volume>27</volume><fpage>313</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1046/j.1440-1681.2000.03240.x</pub-id><pub-id pub-id-type="pmid">10779131</pub-id>
</element-citation></ref><ref id="B84-pharmaceutics-17-00188"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nicholls</surname><given-names>M.</given-names></name>
</person-group><article-title>Nitric oxide discovery Nobel Prize winners: Robert, F.; Furchgott, Louis, J. Ignarro, and Ferid Murad shared the Noble Prize in 1998 for their discoveries concerning nitric oxide as a signalling molecule in the cardiovascular system</article-title><source>Eur. Heart J.</source><year>2019</year><volume>40</volume><fpage>1747</fpage><lpage>1749</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehz361</pub-id><pub-id pub-id-type="pmid">31173095</pub-id>
</element-citation></ref><ref id="B85-pharmaceutics-17-00188"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Noonan</surname><given-names>P.K.</given-names></name>
<name><surname>Gonzalez</surname><given-names>M.A.</given-names></name>
<name><surname>Ruggirello</surname><given-names>D.</given-names></name>
<name><surname>Tomlinson</surname><given-names>J.</given-names></name>
<name><surname>Babcock-Atkinson</surname><given-names>E.</given-names></name>
<name><surname>Ray</surname><given-names>M.</given-names></name>
<name><surname>Golub</surname><given-names>A.</given-names></name>
<name><surname>Cohen</surname><given-names>A.</given-names></name>
</person-group><article-title>Relative bioavailability of a new transdermal nitroglycerin delivery system</article-title><source>J. Pharm. Sci.</source><year>1986</year><volume>75</volume><fpage>688</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1002/jps.2600750715</pub-id><pub-id pub-id-type="pmid">3093667</pub-id>
</element-citation></ref><ref id="B86-pharmaceutics-17-00188"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matsuoka</surname><given-names>H.</given-names></name>
<name><surname>Kuwajima</surname><given-names>I.</given-names></name>
<name><surname>Shimada</surname><given-names>K.</given-names></name>
<name><surname>Mitamura</surname><given-names>H.</given-names></name>
<name><surname>Saruta</surname><given-names>T.</given-names></name>
</person-group><article-title>Comparison of efficacy and safety between bisoprolol transdermal patch (TY-0201) and bisoprolol fumarate oral formulation in Japanese patients with grade I or II essential hypertension: Randomized, double-blind, placebo-controlled study</article-title><source>J. Clin. Hypertens.</source><year>2013</year><volume>15</volume><fpage>806</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1111/jch.12208</pub-id></element-citation></ref><ref id="B87-pharmaceutics-17-00188"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hara</surname><given-names>T.</given-names></name>
<name><surname>Yagi</surname><given-names>S.</given-names></name>
<name><surname>Akaike</surname><given-names>M.</given-names></name>
<name><surname>Sata</surname><given-names>M.</given-names></name>
</person-group><article-title>Transdermal patch of bisoprolol for the treatment of hypertension complicated with aortic dissection</article-title><source>Int. J. Cardiol.</source><year>2015</year><volume>198</volume><fpage>220</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2015.06.112</pub-id><pub-id pub-id-type="pmid">26173061</pub-id>
</element-citation></ref><ref id="B88-pharmaceutics-17-00188"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shinohara</surname><given-names>M.</given-names></name>
<name><surname>Fujino</surname><given-names>T.</given-names></name>
<name><surname>Koike</surname><given-names>H.</given-names></name>
<name><surname>Kitahara</surname><given-names>K.</given-names></name>
<name><surname>Kinoshita</surname><given-names>T.</given-names></name>
<name><surname>Yuzawa</surname><given-names>H.</given-names></name>
<name><surname>Suzuki</surname><given-names>T.</given-names></name>
<name><surname>Fukunaga</surname><given-names>S.</given-names></name>
<name><surname>Kobayashi</surname><given-names>K.</given-names></name>
<name><surname>Aoki</surname><given-names>J.</given-names></name>
</person-group><article-title>Assessment of a novel transdermal selective &#x003b2;1-blocker, the bisoprolol patch, for treating frequent premature ventricular contractions in patients without structural heart disease</article-title><source>J. Cardiol.</source><year>2017</year><volume>70</volume><fpage>212</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/j.jjcc.2017.01.008</pub-id><pub-id pub-id-type="pmid">28343798</pub-id>
</element-citation></ref><ref id="B89-pharmaceutics-17-00188"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kiuchi</surname><given-names>S.</given-names></name>
<name><surname>Hisatake</surname><given-names>S.</given-names></name>
<name><surname>Kabuki</surname><given-names>T.</given-names></name>
<name><surname>Oka</surname><given-names>T.</given-names></name>
<name><surname>Dobashi</surname><given-names>S.</given-names></name>
<name><surname>Fujii</surname><given-names>T.</given-names></name>
<name><surname>Sano</surname><given-names>T.</given-names></name>
<name><surname>Ikeda</surname><given-names>T.</given-names></name>
</person-group><article-title>Bisoprolol transdermal patch improves orthostatic hypotension in patients with chronic heart failure and hypertension</article-title><source>Clin. Exp. Hypertens.</source><year>2020</year><volume>42</volume><fpage>539</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1080/10641963.2020.1723616</pub-id><pub-id pub-id-type="pmid">32009474</pub-id>
</element-citation></ref><ref id="B90-pharmaceutics-17-00188"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yasui</surname><given-names>T.</given-names></name>
<name><surname>Oka</surname><given-names>T.</given-names></name>
<name><surname>Shioyama</surname><given-names>W.</given-names></name>
<name><surname>Oboshi</surname><given-names>M.</given-names></name>
<name><surname>Fujita</surname><given-names>M.</given-names></name>
</person-group><article-title>Bisoprolol transdermal patch treatment for patients with atrial fibrillation after noncardiac surgery: A single-center retrospective study of 61 patients</article-title><source>SAGE Open Med.</source><year>2020</year><volume>8</volume><fpage>2050312120907817</fpage><pub-id pub-id-type="doi">10.1177/2050312120907817</pub-id><pub-id pub-id-type="pmid">32128207</pub-id>
</element-citation></ref><ref id="B91-pharmaceutics-17-00188"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Onesti</surname><given-names>G.</given-names></name>
<name><surname>Bock</surname><given-names>K.D.</given-names></name>
<name><surname>Heimsoth</surname><given-names>V.</given-names></name>
<name><surname>Kim</surname><given-names>K.E.</given-names></name>
<name><surname>Merguet</surname><given-names>P.</given-names></name>
</person-group><article-title>Clonidine: A new antihypertensive agent</article-title><source>Am. J. Cardiol.</source><year>1971</year><volume>28</volume><fpage>74</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/0002-9149(71)90037-3</pub-id><pub-id pub-id-type="pmid">4933458</pub-id>
</element-citation></ref><ref id="B92-pharmaceutics-17-00188"><label>92.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Groom</surname><given-names>M.J.</given-names></name>
<name><surname>Cortese</surname><given-names>S.</given-names></name>
</person-group><article-title>Current pharmacological treatments for ADHD</article-title><source>New Discoveries in the Behavioral Neuroscience of Attention-Deficit Hyperactivity Disorder</source><publisher-name>Springer</publisher-name><publisher-loc>Cham, Switzerland</publisher-loc><year>2022</year><fpage>19</fpage><lpage>50</lpage></element-citation></ref><ref id="B93-pharmaceutics-17-00188"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gossop</surname><given-names>M.</given-names></name>
</person-group><article-title>Clonidine and the treatment of the opiate withdrawal syndrome</article-title><source>Drug Alcohol Depend.</source><year>1988</year><volume>21</volume><fpage>253</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1016/0376-8716(88)90078-6</pub-id><pub-id pub-id-type="pmid">3048954</pub-id>
</element-citation></ref><ref id="B94-pharmaceutics-17-00188"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Popli</surname><given-names>S.</given-names></name>
<name><surname>Stroka</surname><given-names>G.</given-names></name>
<name><surname>Daugirdas</surname><given-names>J.</given-names></name>
<name><surname>Norusis</surname><given-names>M.</given-names></name>
<name><surname>Hano</surname><given-names>J.</given-names></name>
<name><surname>Gandhi</surname><given-names>V.</given-names></name>
</person-group><article-title>Transdermal clonidine for hypertensive patients</article-title><source>Clin. Ther.</source><year>1983</year><volume>5</volume><fpage>624</fpage><lpage>628</lpage><pub-id pub-id-type="pmid">6627288</pub-id>
</element-citation></ref><ref id="B95-pharmaceutics-17-00188"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elliott</surname><given-names>W.J.</given-names></name>
<name><surname>Prisant</surname><given-names>L.M.</given-names></name>
</person-group><article-title>Drug delivery systems for antihypertensive agents</article-title><source>Blood Press. Monit.</source><year>1997</year><volume>2</volume><fpage>53</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/0895-7061(96)82173-X</pub-id><pub-id pub-id-type="pmid">10234092</pub-id>
</element-citation></ref><ref id="B96-pharmaceutics-17-00188"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fujimura</surname><given-names>A.</given-names></name>
<name><surname>Ebihara</surname><given-names>A.</given-names></name>
<name><surname>Ohashi</surname><given-names>K.I.</given-names></name>
<name><surname>Shiga</surname><given-names>T.</given-names></name>
<name><surname>Kumagai</surname><given-names>Y.</given-names></name>
<name><surname>Nakashima</surname><given-names>H.</given-names></name>
<name><surname>Kotegawa</surname><given-names>T.</given-names></name>
</person-group><article-title>Comparison of the pharmacokinetics, pharmacodynamics, and safety of oral (Catapres) and transdermal (M-5041T) clonidine in healthy subjects</article-title><source>J. Clin. Pharmacol.</source><year>1994</year><volume>34</volume><fpage>260</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1002/j.1552-4604.1994.tb03996.x</pub-id><pub-id pub-id-type="pmid">8021335</pub-id>
</element-citation></ref><ref id="B97-pharmaceutics-17-00188"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thakur</surname><given-names>R.</given-names></name>
<name><surname>Anwer</surname><given-names>M.K.</given-names></name>
<name><surname>Shams</surname><given-names>M.S.</given-names></name>
<name><surname>Ali</surname><given-names>A.</given-names></name>
<name><surname>Khar</surname><given-names>R.K.</given-names></name>
<name><surname>Shakeel</surname><given-names>F.</given-names></name>
<name><surname>Taha</surname><given-names>E.I.</given-names></name>
</person-group><article-title>Proniosomal transdermal therapeutic system of losartan potassium: Development and pharmacokinetic evaluation</article-title><source>J. Drug Target.</source><year>2009</year><volume>17</volume><fpage>442</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1080/10611860902963039</pub-id><pub-id pub-id-type="pmid">19527115</pub-id>
</element-citation></ref><ref id="B98-pharmaceutics-17-00188"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cilurzo</surname><given-names>F.</given-names></name>
<name><surname>Minghetti</surname><given-names>P.</given-names></name>
<name><surname>Gennari</surname><given-names>C.G.</given-names></name>
<name><surname>Casiraghi</surname><given-names>A.</given-names></name>
<name><surname>Selmin</surname><given-names>F.</given-names></name>
<name><surname>Montanari</surname><given-names>L.</given-names></name>
</person-group><article-title>Formulation study of a patch containing propranolol by design of experiments</article-title><source>Drug Dev. Ind. Pharm.</source><year>2014</year><volume>40</volume><fpage>17</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.3109/03639045.2012.743559</pub-id><pub-id pub-id-type="pmid">23301830</pub-id>
</element-citation></ref><ref id="B99-pharmaceutics-17-00188"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gul</surname><given-names>R.</given-names></name>
<name><surname>Khan</surname><given-names>Y.</given-names></name>
<name><surname>Aman</surname><given-names>T.</given-names></name>
</person-group><article-title>Formulation and Evaluation of Bisoprolol Hemifumarate Emulgel for Transdermal Drug Delivery</article-title><source>Dissolution Technol.</source><year>2022</year><volume>29</volume><fpage>38</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.14227/DT290522P38</pub-id></element-citation></ref><ref id="B100-pharmaceutics-17-00188"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ammar</surname><given-names>H.</given-names></name>
<name><surname>Ghorab</surname><given-names>M.</given-names></name>
<name><surname>El-Nahhas</surname><given-names>S.</given-names></name>
<name><surname>Kamel</surname><given-names>R.</given-names></name>
</person-group><article-title>Design of a transdermal delivery system for aspirin as an antithrombotic drug</article-title><source>Int. J. Pharm.</source><year>2006</year><volume>327</volume><fpage>81</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2006.07.054</pub-id><pub-id pub-id-type="pmid">16949225</pub-id>
</element-citation></ref><ref id="B101-pharmaceutics-17-00188"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Darwhekar</surname><given-names>G.</given-names></name>
<name><surname>Jain</surname><given-names>D.K.</given-names></name>
<name><surname>Patidar</surname><given-names>V.K.</given-names></name>
</person-group><article-title>Formulation and evaluation of transdermal drug delivery system of clopidogrel bisulfate</article-title><source>Asian J. Pharm. Life Sci. ISSN</source><year>2011</year><volume>2231</volume><fpage>4423</fpage></element-citation></ref><ref id="B102-pharmaceutics-17-00188"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burger</surname><given-names>C.</given-names></name>
<name><surname>Gerber</surname><given-names>M.</given-names></name>
<name><surname>Du Preez</surname><given-names>J.L.</given-names></name>
<name><surname>Du Plessis</surname><given-names>J.</given-names></name>
</person-group><article-title>Optimised transdermal delivery of pravastatin</article-title><source>Int. J. Pharm.</source><year>2015</year><volume>496</volume><fpage>518</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2015.10.034</pub-id><pub-id pub-id-type="pmid">26505148</pub-id>
</element-citation></ref><ref id="B103-pharmaceutics-17-00188"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vitorino</surname><given-names>C.</given-names></name>
<name><surname>Almeida</surname><given-names>J.</given-names></name>
<name><surname>Gon&#x000e7;alves</surname><given-names>L.</given-names></name>
<name><surname>Almeida</surname><given-names>A.</given-names></name>
<name><surname>Sousa</surname><given-names>J.</given-names></name>
<name><surname>Pais</surname><given-names>A.</given-names></name>
</person-group><article-title>Co-encapsulating nanostructured lipid carriers for transdermal application: From experimental design to the molecular detail</article-title><source>J. Control. Release</source><year>2013</year><volume>167</volume><fpage>301</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2013.02.011</pub-id><pub-id pub-id-type="pmid">23454133</pub-id>
</element-citation></ref><ref id="B104-pharmaceutics-17-00188"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sabareesh</surname><given-names>M.</given-names></name>
<name><surname>Khan</surname><given-names>P.R.</given-names></name>
<name><surname>Sudheer</surname><given-names>B.</given-names></name>
</person-group><article-title>Formulation and evaluation of lisinopril dihydrate transdermal proniosomal gels</article-title><source>J. Appl. Pharm. Sci.</source><year>2011</year><fpage>181</fpage><lpage>185</lpage></element-citation></ref><ref id="B105-pharmaceutics-17-00188"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Quinn</surname><given-names>H.L.</given-names></name>
<name><surname>Bonham</surname><given-names>L.</given-names></name>
<name><surname>Hughes</surname><given-names>C.M.</given-names></name>
<name><surname>Donnelly</surname><given-names>R.F.</given-names></name>
</person-group><article-title>Design of a dissolving microneedle platform for transdermal delivery of a fixed-dose combination of cardiovascular drugs</article-title><source>J. Pharm. Sci.</source><year>2015</year><volume>104</volume><fpage>3490</fpage><lpage>3500</lpage><pub-id pub-id-type="doi">10.1002/jps.24563</pub-id><pub-id pub-id-type="pmid">26149914</pub-id>
</element-citation></ref><ref id="B106-pharmaceutics-17-00188"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaur</surname><given-names>M.</given-names></name>
<name><surname>Ita</surname><given-names>K.B.</given-names></name>
<name><surname>Popova</surname><given-names>I.E.</given-names></name>
<name><surname>Parikh</surname><given-names>S.J.</given-names></name>
<name><surname>Bair</surname><given-names>D.A.</given-names></name>
</person-group><article-title>Microneedle-assisted delivery of verapamil hydrochloride and amlodipine besylate</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2014</year><volume>86</volume><fpage>284</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2013.10.007</pub-id><pub-id pub-id-type="pmid">24176676</pub-id>
</element-citation></ref><ref id="B107-pharmaceutics-17-00188"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sardesai</surname><given-names>M.</given-names></name>
<name><surname>Shende</surname><given-names>P.</given-names></name>
</person-group><article-title>Engineering of nanospheres dispersed microneedle system for antihypertensive action</article-title><source>Curr. Drug Deliv.</source><year>2020</year><volume>17</volume><fpage>776</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.2174/1567201817666200804110003</pub-id><pub-id pub-id-type="pmid">32753011</pub-id>
</element-citation></ref><ref id="B108-pharmaceutics-17-00188"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>F.</given-names></name>
<name><surname>Su</surname><given-names>C.</given-names></name>
<name><surname>Yu</surname><given-names>B.</given-names></name>
<name><surname>Liu</surname><given-names>D.</given-names></name>
<name><surname>Chen</surname><given-names>H.-J.</given-names></name>
<name><surname>Lin</surname><given-names>D.-a.</given-names></name>
<name><surname>Yang</surname><given-names>C.</given-names></name>
<name><surname>Zhou</surname><given-names>L.</given-names></name>
<name><surname>Wu</surname><given-names>Q.</given-names></name>
</person-group><article-title>Biodegradable therapeutic microneedle patch for rapid antihypertensive treatment</article-title><source>ACS Appl. Mater. Interfaces</source><year>2019</year><volume>11</volume><fpage>30575</fpage><lpage>30584</lpage><pub-id pub-id-type="doi">10.1021/acsami.9b09697</pub-id><pub-id pub-id-type="pmid">31382742</pub-id>
</element-citation></ref><ref id="B109-pharmaceutics-17-00188"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>C.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>L.</given-names></name>
<name><surname>Zhou</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Yi</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Hu</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
</person-group><article-title>Transdermal hormone delivery: Strategies, application and modality selection</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2023</year><volume>86</volume><fpage>104730</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2023.104730</pub-id></element-citation></ref><ref id="B110-pharmaceutics-17-00188"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Files</surname><given-names>J.</given-names></name>
<name><surname>Kling</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Transdermal delivery of bioidentical estrogen in menopausal hormone therapy: A clinical review</article-title><source>Expert. Opin. Drug Deliv.</source><year>2020</year><volume>17</volume><fpage>543</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1080/17425247.2020.1700949</pub-id><pub-id pub-id-type="pmid">31795776</pub-id>
</element-citation></ref><ref id="B111-pharmaceutics-17-00188"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>P.</given-names></name>
<name><surname>&#x000d6;zel</surname><given-names>B.</given-names></name>
<name><surname>Stanczyk</surname><given-names>F.Z.</given-names></name>
<name><surname>Felix</surname><given-names>J.C.</given-names></name>
<name><surname>Mishell Jr</surname><given-names>D.R.</given-names></name>
</person-group><article-title>The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status</article-title><source>Menopause</source><year>2008</year><volume>15</volume><fpage>94</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1097/gme.0b013e318148b98b</pub-id><pub-id pub-id-type="pmid">17882008</pub-id>
</element-citation></ref><ref id="B112-pharmaceutics-17-00188"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wong</surname><given-names>W.F.</given-names></name>
<name><surname>Ang</surname><given-names>K.P.</given-names></name>
<name><surname>Sethi</surname><given-names>G.</given-names></name>
<name><surname>Looi</surname><given-names>C.Y.</given-names></name>
</person-group><article-title>Recent advancement of medical patch for transdermal drug delivery</article-title><source>Medicina</source><year>2023</year><volume>59</volume><elocation-id>778</elocation-id><pub-id pub-id-type="doi">10.3390/medicina59040778</pub-id><pub-id pub-id-type="pmid">37109736</pub-id>
</element-citation></ref><ref id="B113-pharmaceutics-17-00188"><label>113.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Shafi</surname><given-names>O.</given-names></name>
</person-group><article-title>Engineering for Obstetrics and Gynaecology: Fabrication of the Transdermal Progesterone Patch</article-title><source>Ph.D. Thesis</source><publisher-name>UCL (University College London)</publisher-name><publisher-loc>London, UK</publisher-loc><year>2024</year></element-citation></ref><ref id="B114-pharmaceutics-17-00188"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suriyaamporn</surname><given-names>P.</given-names></name>
<name><surname>Aumklad</surname><given-names>P.</given-names></name>
<name><surname>Rojanarata</surname><given-names>T.</given-names></name>
<name><surname>Patrojanasophon</surname><given-names>P.</given-names></name>
<name><surname>Ngawhirunpat</surname><given-names>T.</given-names></name>
<name><surname>Pamornpathomkul</surname><given-names>B.</given-names></name>
<name><surname>Opanasopit</surname><given-names>P.</given-names></name>
</person-group><article-title>Fabrication of controlled-release polymeric microneedles containing progesterone-loaded self-microemulsions for transdermal delivery</article-title><source>Pharm. Dev. Technol.</source><year>2024</year><volume>29</volume><fpage>98</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1080/10837450.2024.2307996</pub-id><pub-id pub-id-type="pmid">38258531</pub-id>
</element-citation></ref><ref id="B115-pharmaceutics-17-00188"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Banov</surname><given-names>D.</given-names></name>
<name><surname>Biundo</surname><given-names>B.</given-names></name>
<name><surname>Ip</surname><given-names>K.</given-names></name>
<name><surname>Shan</surname><given-names>A.</given-names></name>
<name><surname>Banov</surname><given-names>F.</given-names></name>
<name><surname>Song</surname><given-names>G.</given-names></name>
<name><surname>Carvalho</surname><given-names>M.</given-names></name>
</person-group><article-title>Testosterone Therapy for Late-Onset Hypogonadism: A Clinical, Biological, and Analytical Approach Using Compounded Testosterone 0.5&#x02013;20% Topical Gels</article-title><source>Pharmaceutics</source><year>2024</year><volume>16</volume><elocation-id>621</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics16050621</pub-id><pub-id pub-id-type="pmid">38794283</pub-id>
</element-citation></ref><ref id="B116-pharmaceutics-17-00188"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Varnum</surname><given-names>A.A.</given-names></name>
<name><surname>van Leeuwen</surname><given-names>L.</given-names></name>
<name><surname>Velasquez</surname><given-names>D.A.</given-names></name>
<name><surname>Ledesma</surname><given-names>B.</given-names></name>
<name><surname>Deebel</surname><given-names>N.A.</given-names></name>
<name><surname>Codrington</surname><given-names>J.</given-names></name>
<name><surname>Evans</surname><given-names>A.</given-names></name>
<name><surname>Diaz</surname><given-names>A.</given-names></name>
<name><surname>Miller</surname><given-names>D.</given-names></name>
<name><surname>Ramasamy</surname><given-names>R.</given-names></name>
</person-group><article-title>Testosterone replacement therapy in adolescents and young men</article-title><source>J. Men&#x02019;s Health</source><year>2024</year><volume>20</volume><fpage>24</fpage><lpage>31</lpage></element-citation></ref><ref id="B117-pharmaceutics-17-00188"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vashishth</surname><given-names>R.</given-names></name>
<name><surname>Chuong</surname><given-names>M.C.</given-names></name>
<name><surname>Duarte</surname><given-names>J.C.</given-names></name>
<name><surname>Gharat</surname><given-names>Y.</given-names></name>
<name><surname>Kerr</surname><given-names>S.G.</given-names></name>
</person-group><article-title>Two Sustained Release Membranes Used in Formulating Low Strength Testosterone Reservoir Transdermal Patches</article-title><source>Curr. Drug Deliv.</source><year>2024</year><volume>21</volume><fpage>438</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.2174/1567201820666230316115921</pub-id><pub-id pub-id-type="pmid">36927432</pub-id>
</element-citation></ref><ref id="B118-pharmaceutics-17-00188"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fini</surname><given-names>A.</given-names></name>
<name><surname>Bergamante</surname><given-names>V.</given-names></name>
<name><surname>Ceschel</surname><given-names>G.C.</given-names></name>
<name><surname>Ronchi</surname><given-names>C.</given-names></name>
<name><surname>De Moraes</surname><given-names>C.A.F.</given-names></name>
</person-group><article-title>Control of transdermal permeation of hydrocortisone acetate from hydrophilic and lipophilic formulations</article-title><source>AAPS PharmSciTech</source><year>2008</year><volume>9</volume><fpage>762</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1208/s12249-008-9107-z</pub-id><pub-id pub-id-type="pmid">18563577</pub-id>
</element-citation></ref><ref id="B119-pharmaceutics-17-00188"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Febrianti</surname><given-names>N.Q.</given-names></name>
<name><surname>Aziz</surname><given-names>A.Y.R.</given-names></name>
<name><surname>Tunggeng</surname><given-names>M.G.R.</given-names></name>
<name><surname>Ramadhany</surname><given-names>I.D.</given-names></name>
<name><surname>Syafika</surname><given-names>N.</given-names></name>
<name><surname>Azis</surname><given-names>S.B.A.</given-names></name>
<name><surname>Djabir</surname><given-names>Y.Y.</given-names></name>
<name><surname>Asri</surname><given-names>R.M.</given-names></name>
<name><surname>Permana</surname><given-names>A.D.</given-names></name>
</person-group><article-title>Development of pH-Sensitive Nanoparticle Incorporated into Dissolving Microarray Patch for Selective Delivery of Methotrexate</article-title><source>AAPS PharmSciTech</source><year>2024</year><volume>25</volume><fpage>70</fpage><pub-id pub-id-type="doi">10.1208/s12249-024-02777-y</pub-id><pub-id pub-id-type="pmid">38538953</pub-id>
</element-citation></ref><ref id="B120-pharmaceutics-17-00188"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>M.</given-names></name>
<name><surname>Cao</surname><given-names>J.</given-names></name>
<name><surname>Fang</surname><given-names>T.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Zhen</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>F.</given-names></name>
<name><surname>Yu</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
</person-group><article-title>Applications and recent advances in transdermal drug delivery systems for the treatment of rheumatoid arthritis</article-title><source>Acta Pharm. Sin. B</source><year>2023</year><volume>13</volume><fpage>4417</fpage><lpage>4441</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2023.05.025</pub-id><pub-id pub-id-type="pmid">37969725</pub-id>
</element-citation></ref><ref id="B121-pharmaceutics-17-00188"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>P.-G.</given-names></name>
<name><surname>Lei</surname><given-names>X.-F.</given-names></name>
<name><surname>Ren</surname><given-names>B.-D.</given-names></name>
<name><surname>Lv</surname><given-names>S.-Y.</given-names></name>
<name><surname>Zhang</surname><given-names>J.-L.</given-names></name>
</person-group><article-title>Diclofenac transdermal patch versus the sustained release tablet: A randomized clinical trial in rheumatoid arthritic patients</article-title><source>Trop. J. Pharm. Res.</source><year>2017</year><volume>16</volume><fpage>477</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.4314/tjpr.v16i2.29</pub-id></element-citation></ref><ref id="B122-pharmaceutics-17-00188"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Gao</surname><given-names>Z.</given-names></name>
<name><surname>Chao</surname><given-names>S.</given-names></name>
<name><surname>Lu</surname><given-names>W.</given-names></name>
<name><surname>Zhang</surname><given-names>P.</given-names></name>
</person-group><article-title>Transdermal delivery of inflammatory factors regulated drugs for rheumatoid arthritis</article-title><source>Drug Deliv.</source><year>2022</year><volume>29</volume><fpage>1934</fpage><lpage>1950</lpage><pub-id pub-id-type="doi">10.1080/10717544.2022.2089295</pub-id><pub-id pub-id-type="pmid">35757855</pub-id>
</element-citation></ref><ref id="B123-pharmaceutics-17-00188"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cao</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>N.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Su</surname><given-names>J.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Han</surname><given-names>J.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
</person-group><article-title>Microneedle-assisted transdermal delivery of etanercept for rheumatoid arthritis treatment</article-title><source>Pharmaceutics</source><year>2019</year><volume>11</volume><elocation-id>235</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics11050235</pub-id><pub-id pub-id-type="pmid">31096705</pub-id>
</element-citation></ref><ref id="B124-pharmaceutics-17-00188"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jacobse</surname><given-names>J.</given-names></name>
<name><surname>Ten Voorde</surname><given-names>W.</given-names></name>
<name><surname>Tandon</surname><given-names>A.</given-names></name>
<name><surname>Romeijn</surname><given-names>S.G.</given-names></name>
<name><surname>Grievink</surname><given-names>H.W.</given-names></name>
<name><surname>van der Maaden</surname><given-names>K.</given-names></name>
<name><surname>van Esdonk</surname><given-names>M.J.</given-names></name>
<name><surname>Moes</surname><given-names>D.J.A.</given-names></name>
<name><surname>Loeff</surname><given-names>F.</given-names></name>
<name><surname>Bloem</surname><given-names>K.</given-names></name>
</person-group><article-title>Comprehensive evaluation of microneedle-based intradermal adalimumab delivery vs. subcutaneous administration: Results of a randomized controlled clinical trial</article-title><source>Br. J. Clin. Pharmacol.</source><year>2021</year><volume>87</volume><fpage>3162</fpage><lpage>3176</lpage><pub-id pub-id-type="doi">10.1111/bcp.14729</pub-id><pub-id pub-id-type="pmid">33403697</pub-id>
</element-citation></ref><ref id="B125-pharmaceutics-17-00188"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matsuzaka</surname><given-names>Y.</given-names></name>
<name><surname>Uesawa</surname><given-names>Y.</given-names></name>
</person-group><article-title>A Deep Learning-Based Quantitative Structure&#x02013;Activity Relationship System Construct Prediction Model of Agonist and Antagonist with High Performance</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>2141</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23042141</pub-id><pub-id pub-id-type="pmid">35216254</pub-id>
</element-citation></ref><ref id="B126-pharmaceutics-17-00188"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abdallah</surname><given-names>R.M.</given-names></name>
<name><surname>Hasan</surname><given-names>H.E.</given-names></name>
<name><surname>Hammad</surname><given-names>A.</given-names></name>
</person-group><article-title>Predictive modeling of skin permeability for molecules: Investigating FDA-approved drug permeability with various AI algorithms</article-title><source>PLOS Digital Health</source><year>2024</year><volume>3</volume><elocation-id>e0000483</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pdig.0000483</pub-id><pub-id pub-id-type="pmid">38568888</pub-id>
</element-citation></ref><ref id="B127-pharmaceutics-17-00188"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Defraeye</surname><given-names>T.</given-names></name>
<name><surname>Bahrami</surname><given-names>F.</given-names></name>
<name><surname>Rossi</surname><given-names>R.M.</given-names></name>
</person-group><article-title>Inverse mechanistic modeling of transdermal drug delivery for fast identification of optimal model parameters</article-title><source>Front. Pharmacol.</source><year>2021</year><volume>12</volume><elocation-id>641111</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2021.641111</pub-id><pub-id pub-id-type="pmid">33995047</pub-id>
</element-citation></ref><ref id="B128-pharmaceutics-17-00188"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yazdi</surname><given-names>S.J.M.</given-names></name>
<name><surname>Baqersad</surname><given-names>J.</given-names></name>
</person-group><article-title>Mechanical modeling and characterization of human skin: A review</article-title><source>J. Biomech.</source><year>2022</year><volume>130</volume><elocation-id>110864</elocation-id><pub-id pub-id-type="pmid">34844034</pub-id>
</element-citation></ref><ref id="B129-pharmaceutics-17-00188"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Serrano</surname><given-names>D.R.</given-names></name>
<name><surname>Luciano</surname><given-names>F.C.</given-names></name>
<name><surname>Anaya</surname><given-names>B.J.</given-names></name>
<name><surname>Ongoren</surname><given-names>B.</given-names></name>
<name><surname>Kara</surname><given-names>A.</given-names></name>
<name><surname>Molina</surname><given-names>G.</given-names></name>
<name><surname>Ramirez</surname><given-names>B.I.</given-names></name>
<name><surname>S&#x000e1;nchez-Guirales</surname><given-names>S.A.</given-names></name>
<name><surname>Simon</surname><given-names>J.A.</given-names></name>
<name><surname>Tomietto</surname><given-names>G.</given-names></name>
</person-group><article-title>Artificial intelligence (AI) applications in drug discovery and drug delivery: Revolutionizing personalized medicine</article-title><source>Pharmaceutics</source><year>2024</year><volume>16</volume><elocation-id>1328</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics16101328</pub-id><pub-id pub-id-type="pmid">39458657</pub-id>
</element-citation></ref><ref id="B130-pharmaceutics-17-00188"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ali</surname><given-names>K.A.</given-names></name>
<name><surname>Mohin</surname><given-names>S.</given-names></name>
<name><surname>Mondal</surname><given-names>P.</given-names></name>
<name><surname>Goswami</surname><given-names>S.</given-names></name>
<name><surname>Ghosh</surname><given-names>S.</given-names></name>
<name><surname>Choudhuri</surname><given-names>S.</given-names></name>
</person-group><article-title>Influence of artificial intelligence in modern pharmaceutical formulation and drug development</article-title><source>Future J. Pharm. Sci.</source><year>2024</year><volume>10</volume><fpage>53</fpage><pub-id pub-id-type="doi">10.1186/s43094-024-00625-1</pub-id></element-citation></ref><ref id="B131-pharmaceutics-17-00188"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>He</surname><given-names>W.</given-names></name>
<name><surname>Kong</surname><given-names>S.</given-names></name>
<name><surname>Lin</surname><given-names>R.</given-names></name>
<name><surname>Xie</surname><given-names>Y.</given-names></name>
<name><surname>Zheng</surname><given-names>S.</given-names></name>
<name><surname>Yin</surname><given-names>Z.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>Su</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
</person-group><article-title>Machine Learning Assists in the Design and Application of Microneedles</article-title><source>Biomimetics</source><year>2024</year><volume>9</volume><elocation-id>469</elocation-id><pub-id pub-id-type="doi">10.3390/biomimetics9080469</pub-id><pub-id pub-id-type="pmid">39194448</pub-id>
</element-citation></ref><ref id="B132-pharmaceutics-17-00188"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Biswas</surname><given-names>A.A.</given-names></name>
<name><surname>Dhondale</surname><given-names>M.R.</given-names></name>
<name><surname>Agrawal</surname><given-names>A.K.</given-names></name>
<name><surname>Serrano</surname><given-names>D.R.</given-names></name>
<name><surname>Mishra</surname><given-names>B.</given-names></name>
<name><surname>Kumar</surname><given-names>D.</given-names></name>
</person-group><article-title>Advancements in microneedle fabrication techniques: Artificial intelligence assisted 3D-printing technology</article-title><source>Drug Deliv. Transl. Res.</source><year>2024</year><volume>14</volume><fpage>1458</fpage><lpage>1479</lpage><pub-id pub-id-type="doi">10.1007/s13346-023-01510-9</pub-id><pub-id pub-id-type="pmid">38218999</pub-id>
</element-citation></ref><ref id="B133-pharmaceutics-17-00188"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Biswas</surname><given-names>A.A.</given-names></name>
<name><surname>Dhondale</surname><given-names>M.R.</given-names></name>
<name><surname>Singh</surname><given-names>M.</given-names></name>
<name><surname>Agrawal</surname><given-names>A.K.</given-names></name>
<name><surname>Muthudoss</surname><given-names>P.</given-names></name>
<name><surname>Mishra</surname><given-names>B.</given-names></name>
<name><surname>Kumar</surname><given-names>D.</given-names></name>
</person-group><article-title>Development and comparison of machine learning models for in-vitro drug permeation prediction from microneedle patch</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2024</year><volume>199</volume><elocation-id>114311</elocation-id><pub-id pub-id-type="doi">10.1016/j.ejpb.2024.114311</pub-id><pub-id pub-id-type="pmid">38710374</pub-id>
</element-citation></ref><ref id="B134-pharmaceutics-17-00188"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bagde</surname><given-names>A.</given-names></name>
<name><surname>Dev</surname><given-names>S.</given-names></name>
<name><surname>Sriram</surname><given-names>L.M.K.</given-names></name>
<name><surname>Spencer</surname><given-names>S.D.</given-names></name>
<name><surname>Kalvala</surname><given-names>A.</given-names></name>
<name><surname>Nathani</surname><given-names>A.</given-names></name>
<name><surname>Salau</surname><given-names>O.</given-names></name>
<name><surname>Mosley-Kellum</surname><given-names>K.</given-names></name>
<name><surname>Dalvaigari</surname><given-names>H.</given-names></name>
<name><surname>Rajaraman</surname><given-names>S.</given-names></name>
</person-group><article-title>Biphasic burst and sustained transdermal delivery in vivo using an AI-optimized 3D-printed MN patch</article-title><source>Int. J. Pharm.</source><year>2023</year><volume>636</volume><fpage>122647</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2023.122647</pub-id><pub-id pub-id-type="pmid">36754185</pub-id>
</element-citation></ref><ref id="B135-pharmaceutics-17-00188"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prakashan</surname><given-names>D.</given-names></name>
<name><surname>Kaushik</surname><given-names>A.</given-names></name>
<name><surname>Gandhi</surname><given-names>S.</given-names></name>
</person-group><article-title>Smart sensors and wound dressings: Artificial intelligence-supported chronic skin monitoring&#x02013;A review</article-title><source>Chem. Eng. J.</source><year>2024</year><volume>497</volume><fpage>154371</fpage><pub-id pub-id-type="doi">10.1016/j.cej.2024.154371</pub-id></element-citation></ref><ref id="B136-pharmaceutics-17-00188"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y.-H.</given-names></name>
<name><surname>Li</surname><given-names>Y.-L.</given-names></name>
<name><surname>Wei</surname><given-names>M.-Y.</given-names></name>
<name><surname>Li</surname><given-names>G.-Y.</given-names></name>
</person-group><article-title>Innovation and challenges of artificial intelligence technology in personalized healthcare</article-title><source>Sci. Rep.</source><year>2024</year><volume>14</volume><elocation-id>18994</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-024-70073-7</pub-id><pub-id pub-id-type="pmid">39152194</pub-id>
</element-citation></ref><ref id="B137-pharmaceutics-17-00188"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lundborg</surname><given-names>M.</given-names></name>
<name><surname>Wennberg</surname><given-names>C.</given-names></name>
<name><surname>Lidmar</surname><given-names>J.</given-names></name>
<name><surname>Hess</surname><given-names>B.</given-names></name>
<name><surname>Lindahl</surname><given-names>E.</given-names></name>
<name><surname>Norl&#x000e9;n</surname><given-names>L.</given-names></name>
</person-group><article-title>Skin permeability prediction with MD simulation sampling spatial and alchemical reaction coordinates</article-title><source>Biophys. J.</source><year>2022</year><volume>121</volume><fpage>3837</fpage><lpage>3849</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2022.09.009</pub-id><pub-id pub-id-type="pmid">36104960</pub-id>
</element-citation></ref><ref id="B138-pharmaceutics-17-00188"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Risue&#x000f1;o</surname><given-names>I.</given-names></name>
<name><surname>Valencia</surname><given-names>L.</given-names></name>
<name><surname>Jorcano</surname><given-names>J.</given-names></name>
<name><surname>Velasco</surname><given-names>D.</given-names></name>
</person-group><article-title>Skin-on-a-chip models: General overview and future perspectives</article-title><source>APL Bioeng.</source><year>2021</year><elocation-id>5</elocation-id><pub-id pub-id-type="doi">10.1063/5.0046376</pub-id></element-citation></ref><ref id="B139-pharmaceutics-17-00188"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sutterby</surname><given-names>E.</given-names></name>
<name><surname>Thurgood</surname><given-names>P.</given-names></name>
<name><surname>Baratchi</surname><given-names>S.</given-names></name>
<name><surname>Khoshmanesh</surname><given-names>K.</given-names></name>
<name><surname>Pirogova</surname><given-names>E.</given-names></name>
</person-group><article-title>Microfluidic skin-on-a-chip models: Toward biomimetic artificial skin</article-title><source>Small</source><year>2020</year><volume>16</volume><fpage>2002515</fpage><pub-id pub-id-type="doi">10.1002/smll.202002515</pub-id></element-citation></ref><ref id="B140-pharmaceutics-17-00188"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maharao</surname><given-names>N.</given-names></name>
<name><surname>Antontsev</surname><given-names>V.</given-names></name>
<name><surname>Hou</surname><given-names>H.</given-names></name>
<name><surname>Walsh</surname><given-names>J.</given-names></name>
<name><surname>Varshney</surname><given-names>J.</given-names></name>
</person-group><article-title>Scalable in silico Simulation of Transdermal Drug Permeability: Application of BIOiSIM Platform</article-title><source>Drug Des. Dev. Ther.</source><year>2020</year><volume>14</volume><fpage>2307</fpage><lpage>2317</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S253064</pub-id></element-citation></ref><ref id="B141-pharmaceutics-17-00188"><label>141.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>P.T.</given-names></name>
<name><surname>Budha</surname><given-names>R.R.</given-names></name>
<name><surname>Kumar</surname><given-names>G.R.</given-names></name>
<name><surname>Nagamani</surname><given-names>B.</given-names></name>
<name><surname>Rao</surname><given-names>G.K.</given-names></name>
</person-group><article-title>Exploring Nano-Based Therapeutics by Quantum Computational Modeling</article-title><source>Drug Delivery Systems Using Quantum Computing</source><publisher-name>Wiley</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2024</year><fpage>93</fpage><lpage>139</lpage></element-citation></ref><ref id="B142-pharmaceutics-17-00188"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alowais</surname><given-names>S.A.</given-names></name>
<name><surname>Alghamdi</surname><given-names>S.S.</given-names></name>
<name><surname>Alsuhebany</surname><given-names>N.</given-names></name>
<name><surname>Alqahtani</surname><given-names>T.</given-names></name>
<name><surname>Alshaya</surname><given-names>A.I.</given-names></name>
<name><surname>Almohareb</surname><given-names>S.N.</given-names></name>
<name><surname>Aldairem</surname><given-names>A.</given-names></name>
<name><surname>Alrashed</surname><given-names>M.</given-names></name>
<name><surname>Bin Saleh</surname><given-names>K.</given-names></name>
<name><surname>Badreldin</surname><given-names>H.A.</given-names></name>
</person-group><article-title>Revolutionizing healthcare: The role of artificial intelligence in clinical practice</article-title><source>BMC Med. Educ.</source><year>2023</year><volume>23</volume><elocation-id>689</elocation-id><pub-id pub-id-type="doi">10.1186/s12909-023-04698-z</pub-id><pub-id pub-id-type="pmid">37740191</pub-id>
</element-citation></ref><ref id="B143-pharmaceutics-17-00188"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghanavati</surname><given-names>M.A.</given-names></name>
<name><surname>Ahmadi</surname><given-names>S.</given-names></name>
<name><surname>Rohani</surname><given-names>S.</given-names></name>
</person-group><article-title>A machine learning approach for the prediction of aqueous solubility of pharmaceuticals: A comparative model and dataset analysis</article-title><source>Digit. Discov.</source><year>2024</year><volume>3</volume><fpage>2085</fpage><lpage>2104</lpage><pub-id pub-id-type="doi">10.1039/D4DD00065J</pub-id></element-citation></ref><ref id="B144-pharmaceutics-17-00188"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Srivastava</surname><given-names>N.</given-names></name>
<name><surname>Hinton</surname><given-names>G.</given-names></name>
<name><surname>Krizhevsky</surname><given-names>A.</given-names></name>
<name><surname>Sutskever</surname><given-names>I.</given-names></name>
<name><surname>Salakhutdinov</surname><given-names>R.</given-names></name>
</person-group><article-title>Dropout: A Simple Way to Prevent Neural Networks from Overfitting</article-title><source>J. Mach. Learn. Res.</source><year>2014</year><volume>15</volume><fpage>1929</fpage><lpage>1958</lpage></element-citation></ref><ref id="B145-pharmaceutics-17-00188"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Poustforoosh</surname><given-names>A.</given-names></name>
<name><surname>Hashemipour</surname><given-names>H.</given-names></name>
<name><surname>Pardakhty</surname><given-names>A.</given-names></name>
<name><surname>Pour</surname><given-names>M.K.</given-names></name>
</person-group><article-title>Preparation of nano-micelles of meloxicam for transdermal drug delivery and simulation of drug release: A computational supported experimental study</article-title><source>Can. J. Chem. Eng.</source><year>2022</year><volume>100</volume><fpage>3428</fpage><lpage>3436</lpage><pub-id pub-id-type="doi">10.1002/cjce.24339</pub-id></element-citation></ref><ref id="B146-pharmaceutics-17-00188"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ita</surname><given-names>K.</given-names></name>
<name><surname>Roshanaei</surname><given-names>S.</given-names></name>
</person-group><article-title>Artificial intelligence for skin permeability prediction: Deep learning</article-title><source>J. Drug Target.</source><year>2024</year><volume>32</volume><fpage>334</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1080/1061186X.2024.2309574</pub-id><pub-id pub-id-type="pmid">38258521</pub-id>
</element-citation></ref><ref id="B147-pharmaceutics-17-00188"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chang</surname><given-names>C.C.</given-names></name>
<name><surname>Lin</surname><given-names>C.J.</given-names></name>
</person-group><article-title>LIBSVM: A Library for Support Vector Machines</article-title><source>Acm T Intel. Syst. Tec.</source><year>2011</year><volume>2</volume><fpage>27</fpage><pub-id pub-id-type="doi">10.1145/1961189.1961199</pub-id></element-citation></ref><ref id="B148-pharmaceutics-17-00188"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moss</surname><given-names>G.P.</given-names></name>
<name><surname>Shah</surname><given-names>A.J.</given-names></name>
<name><surname>Adams</surname><given-names>R.G.</given-names></name>
<name><surname>Davey</surname><given-names>N.</given-names></name>
<name><surname>Wilkinson</surname><given-names>S.C.</given-names></name>
<name><surname>Pugh</surname><given-names>W.J.</given-names></name>
<name><surname>Sun</surname><given-names>Y.</given-names></name>
</person-group><article-title>The application of discriminant analysis and Machine Learning methods as tools to identify and classify compounds with potential as transdermal enhancers</article-title><source>Eur. J. Pharm. Sci.</source><year>2012</year><volume>45</volume><fpage>116</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2011.10.027</pub-id><pub-id pub-id-type="pmid">22101136</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-17-00188-f001"><label>Figure 1</label><caption><p>Integration of AI and MLTDDS-based based therapies.</p></caption><graphic xlink:href="pharmaceutics-17-00188-g001" position="float"/></fig><table-wrap position="float" id="pharmaceutics-17-00188-t001"><object-id pub-id-type="pii">pharmaceutics-17-00188-t001_Table 1</object-id><label>Table 1</label><caption><p>Transdermal drug delivery systems (TDDS) for common viral infectious diseases.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cargo</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Indication</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TDDS</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Acyclovir </td><td align="left" valign="middle" rowspan="1" colspan="1">HSV disease</td><td align="left" valign="middle" rowspan="1" colspan="1">Binary Ethosome TDDS</td><td align="left" valign="middle" rowspan="1" colspan="1"> [<xref rid="B39-pharmaceutics-17-00188" ref-type="bibr">39</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Acyclovir</td><td align="left" valign="middle" rowspan="1" colspan="1">HSV disease</td><td align="left" valign="middle" rowspan="1" colspan="1">Water-in-oil microemulsion</td><td align="left" valign="middle" rowspan="1" colspan="1"> [<xref rid="B44-pharmaceutics-17-00188" ref-type="bibr">44</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Acyclovir</td><td align="left" valign="middle" rowspan="1" colspan="1">HSV disease</td><td align="left" valign="middle" rowspan="1" colspan="1">gel plaster</td><td align="left" valign="middle" rowspan="1" colspan="1"> [<xref rid="B48-pharmaceutics-17-00188" ref-type="bibr">48</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Penciclovir</td><td align="left" valign="middle" rowspan="1" colspan="1">HSV disease</td><td align="left" valign="middle" rowspan="1" colspan="1">Hydrogel Nanoemulsion</td><td align="left" valign="middle" rowspan="1" colspan="1"> [<xref rid="B43-pharmaceutics-17-00188" ref-type="bibr">43</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Vaccine</td><td align="left" valign="middle" rowspan="1" colspan="1">Influenza Virus Disease</td><td align="left" valign="middle" rowspan="1" colspan="1"> Egg microneedles</td><td align="left" valign="middle" rowspan="1" colspan="1"> [<xref rid="B45-pharmaceutics-17-00188" ref-type="bibr">45</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Zanamivir </td><td align="left" valign="middle" rowspan="1" colspan="1">Influenza Virus Disease</td><td align="left" valign="middle" rowspan="1" colspan="1">Transdermal patch-control release</td><td align="left" valign="middle" rowspan="1" colspan="1"> [<xref rid="B46-pharmaceutics-17-00188" ref-type="bibr">46</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">5-FU</td><td align="left" valign="middle" rowspan="1" colspan="1">Warts&#x02019; disease</td><td align="left" valign="middle" rowspan="1" colspan="1">Solid microneedles </td><td align="left" valign="middle" rowspan="1" colspan="1"> [<xref rid="B40-pharmaceutics-17-00188" ref-type="bibr">40</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SARS-CoV-2 Vaccine</td><td align="left" valign="middle" rowspan="1" colspan="1">COVID-19 disease</td><td align="left" valign="middle" rowspan="1" colspan="1">Fluorocarbon-modified chitosan (FCS)based transdermal delivery</td><td align="left" valign="middle" rowspan="1" colspan="1"> [<xref rid="B47-pharmaceutics-17-00188" ref-type="bibr">47</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2 Vaccine</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19 disease</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Microneedles TDDS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B42-pharmaceutics-17-00188" ref-type="bibr">42</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-00188-t002"><object-id pub-id-type="pii">pharmaceutics-17-00188-t002_Table 2</object-id><label>Table 2</label><caption><p>Transdermal drug delivery systems (TDDS) for Central Nervous System (CNS) disorders.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Indication</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TDDS</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Nicotine</td><td align="center" valign="middle" rowspan="1" colspan="1">Dementia, Alzheimer&#x02019;s disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Transdermal patch-matrix</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B59-pharmaceutics-17-00188" ref-type="bibr">59</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Physostigmine</td><td align="center" valign="middle" rowspan="1" colspan="1">Alzheimer disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Transdermal patch-control release</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B60-pharmaceutics-17-00188" ref-type="bibr">60</xref>,<xref rid="B61-pharmaceutics-17-00188" ref-type="bibr">61</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Phenserine</td><td align="center" valign="middle" rowspan="1" colspan="1">Cognition impairment</td><td align="center" valign="middle" rowspan="1" colspan="1">Transdermal patch-reservoir type</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B62-pharmaceutics-17-00188" ref-type="bibr">62</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rivastigmine</td><td align="center" valign="middle" rowspan="1" colspan="1">Behavioral disorders</td><td align="center" valign="middle" rowspan="1" colspan="1">Transdermal patch-control release</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B63-pharmaceutics-17-00188" ref-type="bibr">63</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Tacrine</td><td align="center" valign="middle" rowspan="1" colspan="1">Alzheimer disease</td><td align="center" valign="middle" rowspan="1" colspan="1">TDDS by iontophoresis</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B64-pharmaceutics-17-00188" ref-type="bibr">64</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sumatriptan</td><td align="center" valign="middle" rowspan="1" colspan="1">Migraine</td><td align="center" valign="middle" rowspan="1" colspan="1">Transdermal patch-control release</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B65-pharmaceutics-17-00188" ref-type="bibr">65</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Pramipexole</td><td align="center" valign="middle" rowspan="1" colspan="1">Parkinson&#x02019;s disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Transdermal patch</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B66-pharmaceutics-17-00188" ref-type="bibr">66</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Donepezil</td><td align="center" valign="middle" rowspan="1" colspan="1">Alzheimer disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Transdermal patch</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B67-pharmaceutics-17-00188" ref-type="bibr">67</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rotigotine</td><td align="center" valign="middle" rowspan="1" colspan="1">Parkinson&#x02019;s disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Transdermal patch</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B68-pharmaceutics-17-00188" ref-type="bibr">68</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Everolimus</td><td align="center" valign="middle" rowspan="1" colspan="1">Multiple sclerosis</td><td align="center" valign="middle" rowspan="1" colspan="1">Microneedle-based transdermal patch</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B69-pharmaceutics-17-00188" ref-type="bibr">69</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Baclofen</td><td align="center" valign="middle" rowspan="1" colspan="1">Multiple sclerosis</td><td align="center" valign="middle" rowspan="1" colspan="1">Nanosuspension-based microneedle skin patch</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B70-pharmaceutics-17-00188" ref-type="bibr">70</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Asenapine</td><td align="center" valign="middle" rowspan="1" colspan="1">Schizophrenia</td><td align="center" valign="middle" rowspan="1" colspan="1">Transdermal patch</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B71-pharmaceutics-17-00188" ref-type="bibr">71</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Blonaserin</td><td align="center" valign="middle" rowspan="1" colspan="1">Schizophrenia</td><td align="center" valign="middle" rowspan="1" colspan="1">Transdermal patch</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B72-pharmaceutics-17-00188" ref-type="bibr">72</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Clozapine</td><td align="center" valign="middle" rowspan="1" colspan="1">Schizophrenia</td><td align="center" valign="middle" rowspan="1" colspan="1">Nanoemulsion-based transdermal drug delivery system</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B73-pharmaceutics-17-00188" ref-type="bibr">73</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Risperidone</td><td align="center" valign="middle" rowspan="1" colspan="1">Antipsychotic</td><td align="center" valign="middle" rowspan="1" colspan="1">Transferosomal gel-transdermal</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B74-pharmaceutics-17-00188" ref-type="bibr">74</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Olanzapine</td><td align="center" valign="middle" rowspan="1" colspan="1">Antipsychotic</td><td align="center" valign="middle" rowspan="1" colspan="1">Transferosomal TDDS</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B75-pharmaceutics-17-00188" ref-type="bibr">75</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quetiapine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antipsychotic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposomal TDDS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B76-pharmaceutics-17-00188" ref-type="bibr">76</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-00188-t003"><object-id pub-id-type="pii">pharmaceutics-17-00188-t003_Table 3</object-id><label>Table 3</label><caption><p>Transdermal drug delivery systems (TDDS) for Cardiovascular (CV) diseases.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Indication</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TDDS</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Nitroglycerin</td><td align="center" valign="middle" rowspan="1" colspan="1">Angina pectoris</td><td align="center" valign="middle" rowspan="1" colspan="1">Microneedle Transdermal patch</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B85-pharmaceutics-17-00188" ref-type="bibr">85</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Propranolol</td><td align="center" valign="middle" rowspan="1" colspan="1">Antihypertensive</td><td align="center" valign="middle" rowspan="1" colspan="1">Gel-based transdermal patch</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B98-pharmaceutics-17-00188" ref-type="bibr">98</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Bisoprolol</td><td align="center" valign="middle" rowspan="1" colspan="1">Atrial fibrillation</td><td align="center" valign="middle" rowspan="1" colspan="1">Gel-based transdermal patch</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B99-pharmaceutics-17-00188" ref-type="bibr">99</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Clonidine</td><td align="center" valign="middle" rowspan="1" colspan="1">Attention-deficit hyperactivity disorder</td><td align="center" valign="middle" rowspan="1" colspan="1">Polymeric transdermal patch</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B96-pharmaceutics-17-00188" ref-type="bibr">96</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Losartan</td><td align="center" valign="middle" rowspan="1" colspan="1">Antihypertensive</td><td align="center" valign="middle" rowspan="1" colspan="1">Proniosome TDDS</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B97-pharmaceutics-17-00188" ref-type="bibr">97</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Aspirin</td><td align="center" valign="middle" rowspan="1" colspan="1">Antithrombotic</td><td align="center" valign="middle" rowspan="1" colspan="1">Hydrocarbon gel-based TDDS</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B100-pharmaceutics-17-00188" ref-type="bibr">100</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Clopidogrel</td><td align="center" valign="middle" rowspan="1" colspan="1">Antithrombotic</td><td align="center" valign="middle" rowspan="1" colspan="1">Polymeric transdermal patch</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B101-pharmaceutics-17-00188" ref-type="bibr">101</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Pravastatin</td><td align="center" valign="middle" rowspan="1" colspan="1">Antithrombotic</td><td align="center" valign="middle" rowspan="1" colspan="1">emulgel based transdermal patch</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B102-pharmaceutics-17-00188" ref-type="bibr">102</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Simvastatin</td><td align="center" valign="middle" rowspan="1" colspan="1">Hypercholesterolemia </td><td align="center" valign="middle" rowspan="1" colspan="1">Nanostructured lipid carrier-based TDDS</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B103-pharmaceutics-17-00188" ref-type="bibr">103</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lisinopril</td><td align="center" valign="middle" rowspan="1" colspan="1">Congestive heart failure</td><td align="center" valign="middle" rowspan="1" colspan="1">Lipid-based transdermal gels</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B104-pharmaceutics-17-00188" ref-type="bibr">104</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Atorvastatin</td><td align="center" valign="middle" rowspan="1" colspan="1">Hypercholesterolemia </td><td align="center" valign="middle" rowspan="1" colspan="1">Microneedle based TDDS</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B105-pharmaceutics-17-00188" ref-type="bibr">105</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Verapamil hydrochoride and Amlodipine besylate</td><td align="center" valign="middle" rowspan="1" colspan="1">Chronic hypertension</td><td align="center" valign="middle" rowspan="1" colspan="1">Microneedle-based transdermal patch</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B106-pharmaceutics-17-00188" ref-type="bibr">106</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Diltiazem and Nifedipin</td><td align="center" valign="middle" rowspan="1" colspan="1">Chronic hypertension</td><td align="center" valign="middle" rowspan="1" colspan="1">Nanosphere-based microneedle TDDS</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B107-pharmaceutics-17-00188" ref-type="bibr">107</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sodium nitroprusside</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hypertensive emergency </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dissolvable microneedle patch</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B108-pharmaceutics-17-00188" ref-type="bibr">108</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-00188-t004"><object-id pub-id-type="pii">pharmaceutics-17-00188-t004_Table 4</object-id><label>Table 4</label><caption><p>Transdermal drug delivery systems (TDDS) for hormonal imbalance and autoimmune disorders.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Indication</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Formulation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Estrogen, Progesterone</td><td align="center" valign="middle" rowspan="1" colspan="1">Hormonal imbalance, Menopause</td><td align="center" valign="middle" rowspan="1" colspan="1">Transdermal patches, gels</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B111-pharmaceutics-17-00188" ref-type="bibr">111</xref>,<xref rid="B113-pharmaceutics-17-00188" ref-type="bibr">113</xref>,<xref rid="B114-pharmaceutics-17-00188" ref-type="bibr">114</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Testosterone</td><td align="center" valign="middle" rowspan="1" colspan="1">Hormonal imbalance</td><td align="center" valign="middle" rowspan="1" colspan="1">Transdermal gels, patches</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B115-pharmaceutics-17-00188" ref-type="bibr">115</xref>,<xref rid="B116-pharmaceutics-17-00188" ref-type="bibr">116</xref>,<xref rid="B117-pharmaceutics-17-00188" ref-type="bibr">117</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hydrocortisone</td><td align="center" valign="middle" rowspan="1" colspan="1">Inflammation, Hormonal imbalance</td><td align="center" valign="middle" rowspan="1" colspan="1">Transdermal creams, gels</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B118-pharmaceutics-17-00188" ref-type="bibr">118</xref>,<xref rid="B119-pharmaceutics-17-00188" ref-type="bibr">119</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Methotrexate</td><td align="center" valign="middle" rowspan="1" colspan="1">Autoimmune Rheumatoid Arthritis (RA) </td><td align="center" valign="middle" rowspan="1" colspan="1">Transdermal patches</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B119-pharmaceutics-17-00188" ref-type="bibr">119</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hydrocortisone</td><td align="center" valign="middle" rowspan="1" colspan="1">Autoimmune (RA), inflammation</td><td align="center" valign="middle" rowspan="1" colspan="1">Transdermal patches, creams</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B120-pharmaceutics-17-00188" ref-type="bibr">120</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Diclofenac (NSAID)</td><td align="center" valign="middle" rowspan="1" colspan="1">Autoimmune (RA) pain relief</td><td align="center" valign="middle" rowspan="1" colspan="1">Transdermal patches</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B121-pharmaceutics-17-00188" ref-type="bibr">121</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Etanercept (TNF inhibitor)</td><td align="center" valign="middle" rowspan="1" colspan="1">Autoimmune (RA)</td><td align="center" valign="middle" rowspan="1" colspan="1">Transdermal patches, microneedles</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B122-pharmaceutics-17-00188" ref-type="bibr">122</xref>,<xref rid="B123-pharmaceutics-17-00188" ref-type="bibr">123</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adalimumab (TNF inhibitor)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Autoimmune (RA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">microneedle</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B124-pharmaceutics-17-00188" ref-type="bibr">124</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-00188-t005"><object-id pub-id-type="pii">pharmaceutics-17-00188-t005_Table 5</object-id><label>Table 5</label><caption><p>Approaches to resolving problems associated with developing TDDS.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Problem</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Solution</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Approach</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Datasets</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Models</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Results</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Screening of drug molecules and optimizing formulation of skin delivery</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Predict the aqueous solubility of drug compounds.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Develop and evaluate machine learning models using diverse data and representations (ESP maps, molecular graphs, and tabular features).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Four solubility datasets (ESOL, AQUA, PHYS, OCHEM) with 3942 unique molecules.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Graph Convolutional Network (GCN) for molecular graphs, EdgeConv for ESP maps XGBoost with selected tabular features Ensemble of all three models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Provides a valuable tool for drug discovery.<break/>Enables early identification and mitigation of solubility issues.<break/>Improves the efficiency of drug development processes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B143-pharmaceutics-17-00188" ref-type="bibr">143</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">skin permeability is crucial for successful TDDS.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Improve accurate prediction of skin permeability</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Evaluate the accuracy of machine learning models (LGBM, XGBoost, CatBoost) on skin permeability.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Compiled a dataset of 441 molecules with diverse skin permeability values (LogKp).<break/>Identified the key descriptors&#x02019; effects (hydrophobicity, hydrogen bonding, and polar surface area on skin permeability).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Employed various machine learning models (MLR, RF, XGBoost, CatBoost, LGBM, ANN) for regression analysis.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LGBM, XGBoost, CatBoost) showed superior predictive accuracy. <break/>Key descriptors like hydrophobicity, hydrogen bonding, and topological polar surface area significantly influence permeability.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B144-pharmaceutics-17-00188" ref-type="bibr">144</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Simulation and Virtual Testing:</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Simulated values for key pharmacokinetic parameters.<break/>and Predicted drug concentrations.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Development of &#x0201c;BIOiSIM,&#x0201d; a physiologically based transdermal platform for predicting drug exposure</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BIOiSIM model utilizes human clinical trials, including drug concentration-time profiles (plasma, tissues), preclinical data, and data from animal studies, including pharmacokinetic parameters and pharmacodynamic responses.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BIOiSIM platform includes:<break/>16-compartment model, a structure representing the pharmacokinetic processes within the body, and Machine learning algorithms.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Accurate Predictions: The model demonstrated good accuracy in predicting drug exposure (AUC, Cmax, Tmax) for three different drugs (morphine, buprenorphine, and nicotine) compared to clinical data.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B140-pharmaceutics-17-00188" ref-type="bibr">140</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-00188-t006"><object-id pub-id-type="pii">pharmaceutics-17-00188-t006_Table 6</object-id><label>Table 6</label><caption><p>Pros and Cons of AI in TDDS.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pros</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cons</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enhanced Formulation Accuracy:<break/>AI models can analyze vast datasets of formulation parameters (e.g., drug properties, excipients, manufacturing conditions) and predict optimal combinations [<xref rid="B145-pharmaceutics-17-00188" ref-type="bibr">145</xref>].<break/>Identify complex interactions between formulation components that may not be apparent to human experts [<xref rid="B144-pharmaceutics-17-00188" ref-type="bibr">144</xref>].<break/>Improved Success Rate:<break/>AI models can predict the likelihood of successful TDD formulations based on historical data and identify potential pitfalls.<break/>Help minimize formulation failures and reduce the risk of expensive clinical trials.<break/>Reduced Experimental Costs:<break/>AI can significantly reduce research and development costs by accelerating the formulation development process and minimizing the number of costly experiments [<xref rid="B30-pharmaceutics-17-00188" ref-type="bibr">30</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Data Dependence:<break/>Relies heavily on high-quality, diverse, and unbiased training data. Limited or biased data can lead to inaccurate predictions [<xref rid="B145-pharmaceutics-17-00188" ref-type="bibr">145</xref>].<break/>Model Complexity: <break/>Some AI models, particularly deep learning models, can be complex and difficult to interpret.<break/>Limited Generalizability: <break/>Models may overfit the training data, leading to poor performance on new, unseen formulations. e.g., Overfitting in Deep Neural Networks (DNNs) [<xref rid="B146-pharmaceutics-17-00188" ref-type="bibr">146</xref>].<break/>Computational Cost:<break/>Concerns about data privacy and security when using patient data to train AI models.<break/>Data sensitivity:<break/>Some AI tools are noise Sensitivity, which means errors or random fluctuations can negatively impact AI performance.<break/>Noisy data can lead to overfitting, where the model performs well on the training data but poorly on new, unseen data. e.g., data sensitivity in SVMs.<break/>[<xref rid="B147-pharmaceutics-17-00188" ref-type="bibr">147</xref>,<xref rid="B148-pharmaceutics-17-00188" ref-type="bibr">148</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>